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BAG-1 SILENCING ENHANCED CISPLATIN OR PACLITAXEL-INDUCED 
APOPTOSIS IN MCF-7 BREAST CANCER CELLS 
SUMMARY 
The multifunctional anti-apoptotic Bag-1 (Bcl-2 athanogene) protein has several 
interaction partners, such as nuclear hormone receptors, anti-apoptotic Bcl-2 protein, 
Hsp70/Hsc70 heat shock protein family, growth hormone receptors, Raf-1 serine 
threonine kinase family, that have important roles in cell involving the regulation of 
cell survival, cell proliferation, cell signalling and apoptosis.  
 
Bag-1 protein consists of three different isoforms produced by alternative translation 
from the same mRNA. Bag-1L (50 kDa) is the least expressed isoform of Bag-1 and 
localized in the nucleus due to its Nuclear Localization Signal (NLS). Bag-1M (46 
kDa) partitions betweenthe nucleus and the cytoplasm.Bag-1S (36 kDa) is the most 
expressed isoform of Bag-1 localized in the cytoplasm.  
 
Elevated levels of Bag-1 expression were observed in various cancer cells, thereby, 
linking the overexpression of Bag-1 with the development of cancer. The most 
striking interactions of Bag-1 are with Bcl-2 and Hsp 70. These interactions of Bag-1 
can enhance the survival potential of cancer cells against stress conditions. Classical 
chemotherapeutic drugs has been used for many years for the treatment of various 
cancer types, but the downregulation of some genes that have roles in cancer 
development represents a new approach to enhance the cell death mechanism. By 
this way, the side effects of drugs or resistance to drugs can be minimized. With this 
motivation, we decided to examine the effects of Bag-1 silencing in cisplatin or 
paclitaxel-induced apoptosis in MCF-7 cells.  
 
We determined that cisplatin and paclitaxel decreased the cell viability of MCF-7 
cells in a time and dose dependent manner, as confirmed with the MTT cell viability 
assay. Therefore, both drugs were used to induce apoptosis in MCF-7 cells. We 
showed that silencing of Bag-1 was effective to downregulate all Bag-1 isoforms, 
and cisplatin or paclitaxel treatment following Bag-1 silencing abolished the Bag-1 
expression whichwas investigated by immunoblotting analysis. We determined the 
effect of cisplatin or paclitaxel and/or Bag-1 silencing in cell proliferation or cell 
death mechnanisms of MCF-7 cells by trypan blue dye exclusion assay and apoptotic 
cell death Elisa assay. The most important features of apoptosis are DNA 
fragmentation, nuclear condensation, cell shrinkage, mitochondrial membrane 
permeabilization loss andmembrane blebbing. We observed these signs of apoptosis 
in cisplatin or paclitaxel and/or Bag-1 siRNA treated MCF-7 cells by propidium 
iodide (PI), DiOC6, acridine orange/ethidium bromide (AO/EB) and DAPI staining.  
xxii 
 
The role of Bag-1 silencing in cisplatin or paclitaxel-induced apoptosis was 
investigated by comparing the expression levels of anti-apoptotic and pro-apoptotic 
Bcl-2 family members usingimmnublotting assay.  
It was observed that each drug was effective to downregulate the anti-apoptotic Bcl-2 
family members (Bcl-2 and Bcl-xL) and upregulate the pro-apoptotic Bax, Bak, Bid, 
Bad, Noxa and Puma expression, and silencing of Bag-1 enhanced these effects. Cell 
cycle machinery was analyzed by flow cytometer to observe the apoptotic functions 
of drugs and/or Bag-1 siRNA and it was found that Bag-1 silencing caused the 
accumulation of sub-G1 phase which is indicative of apoptotis. 
 
To confirm that Bag-1 expression level was important for cell proliferation, cell 
survival or apoptotic mechanism, MCF-7 cells were transfected with human specific 
Bag-1L plasmid and stable colonies were selected. We examined that Bag-1L 
overexpression upregulated Bag-1 isoforms, enhanced the cell proliferation potential 
and decreased the apoptotic potential of both drugs was investigated by 
immunoblotting and cell death Elisa assay.  
 
The functional role of Bag-1 in cisplatin or paclitaxel-induced apoptosis in 
association with polyamine signaling pathway was investigated in polyamine (PA) 
metabolism. Elevated intracellular polyamines are generally proposed as a final 
consequence of deregulated polyamine metabolism in cancer cells. Polyamines; 
putrescine, spermidine and spermine, are regulated by the biosyntheticornithine 
decarboxylase (ODC) enzyme and catabolic polyamine oxidase (PAO) and 
Spermidine/spermine-N1-acetyltransferase (SSAT) enzymes. However, 
overexpression of Bag-1 led to upregulation of ODC levels, silencing of Bag-1 
caused the upregulation of PAO and SSAT levels. In addition, silencing of Bag-1 
increased the generation of byproducts of PA metabolism, Reactive Oxygen Species 
(ROS), on during cisplatin or paclitaxel-induced apoptosis. 
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BAG-1’IN SUSTURULMASI MCF-7 MEME KANSERİ HÜCRELERİNDE 
SİSPLATİN YA DA PAKLİTAKSEL İLE TETİKLENEN APOPTOZU 
ARTTIRMAKTADIR 
ÖZET 
Çok fonksiyonlu apoptoz karşıtı Bag-1 proteini (Bcl-2 assosiye gen) hücre içerisinde 
önemli fonksiyonları olan nuclearhormone reseptörleri, Bcl-2 proteini, Hsp70/ Hsc70 
ısı şok proten ailesi, büyüme hormone reseptörleri, Raf-1 serin/treoninkinaz ailesi 
gibi birçok molekül ile etkileşimde bulunmaktadır. Bu nedenle, Bag-1 hücre 
büyümesini ve proliferasyonunu, hücre sinyal yolaklarını ve apoptoz mekanizmasını 
düzenlemede rol almaktadır.  
 
Bag-1 proteinin hücre içerisinde farklı yerlede lokalize olan 3 izoformu 
bulunmaktadır. Bag-1L izoformu 50 kDa olup, nüklear lokalizasyon sinyali (NLS) 
sayesinde nukleusta konumlanmaktadır. Bag-1M izoformu 46 kDa olup nukleus ve 
sitoplazma arasında konumlanmaktadır. Bag-1S ise 36 kDa olup sitoplazmada 
lokalize olmuştur. 
 
Birçok kanser çeşidinde Bag-1’ın ekspresyon seviyesinde artış görülmektedir. Bu 
artış, Bag-1’ın etkileşimde bulunduğu moleküller ile gerçekleşmekte ve en önemli 
etkileşimini Bcl-2 ve Hsp70 ile göstermektedir. Bu sayede Bag-1 çeşitli stres 
faktörleri karşısında hücrelerin sağ kalımını arttırıcı etki göstermektedir. Kanser 
tedavilerinde klasik kemoterapötik ilaç uygulamaları uzun süredir kullanılmaktadır 
ancak kanser gelişiminde rol oynayan bazı genlerin geçici olarak susturulması ve 
protein ekspresyon seviyelerinin azaltılması ile hücreleri ölüme götürmeyi 
hedeflemek yeni uygulamalardan biridir. Bu yöntem ile hem ilaçların yan etkilerini 
azaltılmakta hem de hücrelerin ilaçlara karşı oluşturduğu resistans mekanizması 
ortadan kaldırılmaktadır. Bu nedenle çalışmamızda, Bag-1’ın geçici olarak 
susturulmasının MCF-7 hücrelerinde sisplatin ya da paklitaksel ile 
tetiklenenapoptotik mekanizmadaki rolü araştırılmıştır. 
 
Öncelikle zamana bağlı sisplatin ya da paklitaksel uygulamasının MCF-7 
hücrelerinin sağ kalımını azalttığı MTT Hücre canlılığı testi ile gösterilmiştir. Her iki 
ilacın da Bag-1 ekspresyonunu azalttığı immünoblotlama ile gösterilmiştir. Bag-1’ın 
geçici olarak susturulmasının tüm izoformlar üzerinde etkili olduğu ve susturulmayı 
takiben uygulanan sisplatin ya da paklitakselin Bag-1 ekspresyonunu oldukça 
azalttığı immunoblotlama ile gösterilmiştir. Bunun yanında, Bag-1 siRNA 
uygulaması ile birlikte sisplatin ya da paklitakselin tetiklediği apoptozda, hücrelerin 
morfolojik olarak gösterdiği değişiklikler gösterilmiştir. Apoptozun önemli 
göstergelerinden olan DNA kırıklarının oluşumu, nüklear kondensasyon, mitokondri 
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membran permeabilitesindeki azalma ya da apoptotik ve lizozomik vesiküllerin 
oluşumu PI, DiOC6, AO/EB ve DAPI boyaması ile gösterilmiştir.  
 
Pro-apoptotik ve anti-apoptotik Bcl-2 ailesi proteinlerinin ekspresyon seviyelerindeki 
değişiklik sisplatin ya da paklitaksel uygulanan MCF-7 normal ve Bag-1 susturulmuş 
hücrelerde immünoblotlama ile gösterilmiş ve pro-apoptotik Bcl-2 ailesi 
proteinlerinin ekspresyon seviyelerinde artış gözlenirken, anti-apoptotik Bcl-2 ailesi 
proteinlerinin ekspresyon seviyelerinde azalma gözlenmiştir. Çoğu kanser tipinde 
mutasyona sahip olan tümör supressör p53 proteininin ve p53’ün hedef genlerinin 
ürünleri olan Puma ve Noxa proteinlerinin ekspresyon seviyelerindeki değişiklik 
Bag-1’ın susturulduğu hücrelerde cisplatin ya da paclitaxel varlığında çalışılmıştır.  
 
Bunun yanında akım sitometrisi ile Bag-1’ın hücre siklusu üzerindeki etkisi 
araştırılmış ve Bag-1 susturulmasını takiben uygulanan ilaçların apoptoz göstergesi 
olan sub-G1 fazında artışa neden olduğu gösterilmiştir. Hücre siklusunda önemli 
görevleri olan siklinler ve sikline bağlı kinaz proteinlerinin ekspresyon 
seviyelerindeki değişiklik incelenmiştir. Kullanılan cisplatin ya da paclitakselin, 
çeşitli kanser tiplerinde G2/M fazında hücre döngüsünde tutuklanmaya sebep 
oldukları bilinmektedir ancak Bag-1 siRNA hücre döngüsünde meydana gelen 
değişiklikler daha önce araştırılmadığı için, bu çalışmanın amaçlarından birisi 
olmuştur.   
 
Apoptoz yolağının en önemli parametrelerinden birisi olan kaspazların aktif hale 
gelmesi ve kaspaz yolağını aktive etmeleri cisplatin ya da paclitaksel uygulanan Bag-
1 susturulmuş ve doğal tip hücrelerde zamana bağlı olarak araştırılmıştır. Zamana 
bağlı ilaç uygulamaları ile kaspazların kesilmiş formlarında artış gözlemlenmiş ve 
Bag-1 siRNA varlığında bu kesilmiş formların ekspresyon seviyelerinde artış 
gözlemlenmiştir.   
 
Bag-1’ın ekspresyon seviyesindeki değişimin hücrelerin büyümesi, canlılığı, 
proliferasyonu ve apoptoz mekanizması üzerinde farklı etkilere sahip olduğunun 
doğrulanması amacı ile Bag-1’ın geçici olarak susturulmasının yanında Bag-1L 
genine sahip plazmid vektör transfeksiyonu ile MCF-7 hücrelerinde Bag-1’ın stabil 
olarak ekspresyonu arttırılmıştır. Bag-1’ın ekspresyon seviyesindeki artışın 
hücrelerin sağ kalımında ve proliferasyonunda artışa neden olduğu belirlenmiş ve 
ekspresyon seviyesindeki bu artışın sisplatinya dapaklitaksel uygulamalarına karşı 
koruma meydana immünoblotlama ile gösterilmiştir. 
 
Bag-1 proteinin sisplatin ya da paklitaksel ile tetiklenen apoptoz mekanizmasındaki 
rolü Polyamin metabolizması ile ilişkilendirilerek araştırılmıştır. Hücrelerin 
canlılığının korunma, çoğalma ve büyüme mekanizmalarında rol oynayan 
poliaminleramin türevli organik bileşiklerdir. Birçok farklı kanser tipinde hücre içi 
poliamin miktarlarında artış gözlemlenmiştir. Putresin, spermidin ve spermin bu 
mekanizmalarda görev alan önemli poliaminlerdendir ve 
biyosentezleriOrnitinDekarboksilaz (ODC) enzimi ile kontrol edilirken, katabolik 
yolakları Poliaminoksidaz (PAO) ve Spermidin/spermin-N1-asetiltransferaz (SSAT) 
enzimi ile kontrol edilmektedir. Bag-1 aşırı ekspresyonuna sahip hücrelerde normal 
hücrelere kıyasla ODC ekspresyonu artış gösterirken, Bag-1’ın susturulmasının da 
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katabolik enzimlerden PAO ve SSAT ekspresyonunda artışa sebep olduğu 
immunoblotlama ile belirlenmiştir. Poliamin yolağının yan ürünleri olarak açığa 
çıkan Reaktif Oksijen Türleri (ROS), Bag-1’ın susturulması ile artış göstermektedir.  
 
Özetle, bu çalışmanın en önemli amacı Bag-1’ın susturulmasını takiben uygulanan 
ilaçlar varlığında tetiklenen apoptotik mekanizmasının farklı parametreler ile 
gösterilmesidir. Bunun için kullanılan parametler, apoptozun hangi yoldan ilerlediği, 
bunun için hangi protein ya da protein ailelerine bağlı kaldığını açığa çıkarmaktadır. 
Kanser hücrelerinin apoptoza yönelmesinde ilaç uygulamalarının yan etkilerini 
ortadan kaldırmaya yönelik olarak geliştirilen yeni çalışmalarda Bag-1 siRNA’ nın 
potansiyel kullanımını arttırmak amaçlanmaktadır.   
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1.  INTRODUCTION 
1.1 Breast Cancer 
Breast cancer is originated from aberrant growing or proliferation of cells in breast 
tissue. Breast tissueis composed of highly branched duct system connected with 
lymph nodes, adipose and connective tissues. Hormones such as; estrogen and 
progesterone control duct system cells. Development of duct system by hormonal 
changes allows proliferation and accumulation of connective and adipose tissues. 
Uncontrolled proliferation of epithelial cells of ducts causes transformation of 
epithelial cells to malignant cancer cells [1]. 
1.1.1 Types of breast cancer 
1.1.1.1 Ductal carcinoma in situ (DCIS) 
The pre-invasiveform of breast cancer, DCIS,is formed by non-invasive tumor cells 
in milk ducts. In situ refers that the cancer is in its original place. Although DCIS 
does not spread to surrounding tissues, suffering from DCIS might enhance the risk 
of invasive breast cancer development. Recent studies indicate that the risk of DCIS 
in women is uncommon in under 30 years of age but increases between 45- 65 and 
decreases later 65 years of ageIn addition, every 1 women in 4 women is diagnosed 
with DCIS means that 25% of all breast cancersdiagnosed by ductal carcinoma [2]. 
The aim in DCIS diagnosis is to be able to keep DCIS under control with 
mammography and surgery. Altough mammography is the early stage screening 
programme that is beneficial for the diagnosis of DCIS, surgery is a clinical approach 
for prevent the invasion of DCIS into other tissues and become invasive [3]. The rate 
of mortality is low in this type of breast cancer and classical chemotherapeutics such 
as tamoxifen is used for treatment of DCIS [4]. 
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1.1.1.2 Invasive ductal carcinoma (IDC) 
IDC is the most common invasive form of breast cancer with the 80% incidence of 
all breast cancer types. Cancer begins at ductal cells and metastasizes to surrounding 
connective tissues. 
Previous studies showed that, the tumor grade of IDC is related with the 
overexpression of human epidermal growth factor receptor 2 protein (HER-2) and 
expression of estrogen receptor (ER) [5]. The frequent differences between DCIS 
and IDC include the (i)incrase in tumor volume, (ii) metastasis to other parts of the 
breast, (iii) enhancement of the aggressiveness potential of tumors, (iv) upregulation 
of the cancer biomarkers expression levels [6, 7]. In addition, IDC shows various 
histological and pathological diversities such as cell polarity alternations, incrase in 
the intraductal component of breast within fibroadenoma. These suggest that IDC 
metastatis occurs not only at the ductal area of breast tissue both also at other parts of 
the tissue [8]. Physical self-examination of breast, mammography and biopsy are 
procedures to diagnose IDC. 
1.1.1.3 Lobular carcinoma In Situ (LCIS) 
While the majority of breast cancers are originated from ducts but LCIS is a non-
invasive form of breast cancer.In this form uncontrolled proliferation and growth of 
benign cells caused cancer in lobules of breast. Lobules are responsible for the 
production of milk. LCIS does not affect to other tissues as it remains in situ [9].The 
prevelance is one in third women regardless of age and the mammographic 
abnormalities or palpable mass is the common characterictics of LCIS [10]. Surgery 
and mastectomy are the treatment methods for this cancer type. 
1.1.1.4 Invasive lobular carcinoma (ILC) 
ILC is an invasive form of in the epithelial cells in milk-producing lobules and 
spreads to other tissues. According to the America Cancer Society reports, about 
10% of breast cancer patients are suffering from ILC. Invasive lobular carcinoma 
cells break the membrane of the lobules and spread other parts of the body [11]. Like 
other invasive form of breast cancer treatments, surgery or chemotherapy is common 
treatment models for LCIS.  
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1.1.1.5 Inflammatory breast carcinoma (IBC) 
IBC is seen rarelybut is the most aggresive form of breast cancer found in young 
women with the symptoms of swelling, redness or an inverted nipple of breast [12]. 
Inflammatory breast cancer cells divide, grow and spread very fast within days and 
the mortality rates are higher than other forms of breast cancer cells [13]. According 
to the National Cancer Institute reports, about 5% of all breast cancer patients have 
IBC in United States. Mastectomy or radiotherapy might be common methods for all 
breast cancer types but IBC requires more complex treatment methods with 
combination of chemotherapy and radiotherapy or following mastectomy, 
chemotherapy and radiotherapy treatment can be performed to suppress the effect or 
IBC [14].  
1.1.2 Reasons of breast cancer 
Development of breast cancer is highly regulated by hormonal status rather than 
other cancer causing agents such as chemicals, radiaton, oncogenic activity, 
inhibitions on tumor supressors. In this situation, female sex hormone estrogen and 
its specific receptor ER gains importance to figure out the regulatory mechanism of 
breast cancer. Estrogen is a steroid hormone that regulates the hormonal balance, cell 
proliferation and DNA repair in females. Estrogen binds to its specific receptor, ER, 
on nuclear membrane and ER controls transcription of various genes. There are two 
types of ER; ER-α and ER-β. Although the chemical structure of these two types 
receptors are similar, ER-α is upregulated and ER-β is downregulated in many breast 
cancers [15].Both ER-α and ER-β is activated via estrogen in breast cancer, but most 
of the human breast cancer cells haveER-α [16]. Estradiol, the type of estrogen 
produced by ovaries,increase the cell survival of MCF-7 cells via upregulating 
mitogen activated protein kinase (MAPK), inhibitor of apoptosis (IAP) family 
member proteins, anti-apoptotic Bcl-2 and c-Myc oncogene [17]. Therefore, 
potential chemotherapeutics such as tamoxifen and aromatase inhibitors or anti-
estrogens gain significance to treat estrogen-dependent breast cancer progression 
[18]. 
The tumor suppressor breast cancer 1, early onset (BRCA1) and breast cancer 2, 
early onset (BRCA2) proteins are associated with breast cancer. BRCA1 is 
responsible for inhibiting the transcriptional activation of ER and BRCA2 has a role 
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in the repairing mechanism of DNA damage. Providing mutations on BRCA1 or 
BRCA2 enhances the risk of developing breast cancer.[19].Mutations on BRCA1 
consists of 5% of all types of cancer and 50% of breast cancer types [20]. In addition, 
presence of one or both of these mutations in women at the age of 20’s is more 
dangerous than in women at 50’s to enhance the breast cancer risk [21]. Previous 
studies show that however, BRCA1 levels are downregulated in G0 and G1 phases at 
the cell cycle, it is highly upregulated in G1/2 transition,thus it confirmes that the 
expressions of BRCA1 and BRCA2 is observed in proliferating and differentiating 
cells [22]. BRCA1 has a role in repairing oxidative DNA damage via interacting with 
p53 tumor suppressor protein and leads the upregulation of p21 and Bax expression 
level by p53-dependent transcription regulation activity [23]. BRCA2 is responsible 
for the perfect DNA repair mechanism as a tumor suppressor protein and deficiencies 
on BRCA2 protein cause nonhomologous end joining of wrong rearrangements in 
DNA repair and increase the breast cancer development [24]. It is observed that 
depletion of estrogen level causes downregulation of BRCA1 levels in MCF-7 (ER+) 
cells, therefore estrogen is a factor inducing the expression of BRCA1 [25]. In 
addition insulin, progresteron and growth factor receptors such as epidermal growth 
factor receptor (EGFR) are important factors for the development of breast cancer 
via activating MAPK signaling cascade and enhancing the expression levels of 
oncogenes [26]. 
The familial history is important for development of breast cancer risks. Women who 
has breast cancer records in their family history are more likely to have breast cancer 
than those who do not have similar historical backround in family [27]. Early 
menarche (menstrual cycle), obesity and late menopause (after the age of 55) 
enhance the risk of breast cancer [28-30]. Another possible factor for the causes of 
breast cancer is aging. It has been suggested that the young women are at lower risk 
level having breast cancer comparing with elderly women [31]. 
1.1.3 Diagnosis and treatment of breast cancer 
The better way to detect early symptoms of breast cancer is physical examination or 
clinical breast examination (CBE), with this process the size, shape, and color or 
symmetry changes of breast tissue is investigated. According to the American Cancer 
Society recommendation, physical and visual examination process should repeate 
once a month and CBE should repeate every 3 years periods.  
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Besides this, mammography is an early screening method for breast cancer and it is 
performed by low dose X-ray beam to detect the irregularity of breast tissue. It has 
been suggested from National Cancer Institute and American Cancer Society that 
women who are over 40 should have mammography once a year. 
After the detection and diagnosis period of breast cancer development, various 
methods are used for the treatment of breast cancer. Surgery is a local therapy of 
breast cancer treatment. Generally, two types of surgical operation are considered in 
the treatment of breast cancer cases. Lumpectomy is proceeded for non-invasive or 
least invasive form of breast cancer types like DCIS by removing the tumor and the 
surrounding tissue. Other opition is mastectomy thatis used for remove of the whole 
breast. 
Radiation therapy isanother local therapy method that damages cancer cells via 
specific laser beam. After surgery, radiation therapy can be used to treat this area and 
reduce the risk of regeneration of cancer. The laser beam affectsmore cancer cells 
rather than normal cells, therefore side effects of radiotherapy are limited with this 
area [32]. 
Instead of radiation therapy, hormonal therapy is used to treat cancer cells. 
Hormones are responsible for the survival and growth of cancer cells, overexpression 
of hormones lead to transcription of some genes. The hormonal therapy based on the 
inhibiton or suppression of hormonal stimuli. Chemotherapeutic drugs, inhibitors or 
anti-sense molecules are potential hormonal therapy agents to block the development 
of cancer cells [33].The most important chemotherapeutic agents that are used to 
treat breast cancer areherceptin,tamoxifen, docetaxel, and cisplatin that are 
mentioned at 1.3 Conventional chemotherapeutic agents to treat breast cancer 
section. 
Neoadjuvant chemotherapy is type of chemotherapy method to decrease the size and 
extent of tumor before the surgical treatment such as mastectomy.Thies method is 
important to understand the effectiveness of chemotherapeutic drugs specific to 
tumor type [34].  
1.2 Conventional chemotherapeutic agents to treat breast cancer 
Classical chemotherapeutics are performed alone or combination with other drugs or 
therapy methods to treat breast cancer cells. The main chemotherapeutic agents 
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might be alklytaing agents and platinum-based drugs such as; cisplatin, 
antimetabolites and organic drugs to activate death mechanisms in the cell such as; 
paclitaxel. Most of them are derived from plants and organic compounds [35]. 
1.2.1 Cisplatin 
Cisplatin (DDP) is cis-diamminedichloroplatinium (II) was discovered at 1960s and 
is a widely usedplatinum-based chemotherapeutic agent in the treatment of different 
cancer types such as; breast, ovary, testes, head and neck cancers [36, 37].  
The structure of water-soluble cisplatin consists of Pt atom at the center with 
covalently bound NH3 and Cl-included functional groups. The structure of cisplatin 
is shown in Figure 1.1. 
 
Figure 1. 1 :The chemical structure of cisplatin, adapted from [37]. 
 
Cisplatin is treated to cancer patient intravenously diluted in saline solution (PBS or 
salt) and in bloodstream it remains intact via high concentration of Cl
-
 ions (100 
mM). The drug enters the cell with passive diffusion or active uptake. The phase III 
trials of cisplatin have strong effects to treat non-small-cell lung cancer (NSCLC) 
alone or with taxanes [38]. The recognition of DNA damage and repair, DNA 
replication and transcription, cell-cycle regulation and apoptosis mechanisms are 
undercontrol of this anti-cancer agent. Binding of cisplatin to DNA leads to the 
inhibition of replication and transcription mechanisms and induction of apoptosis 
[39, 40]. 
The function of cisplatin as aninorganic neutral platinum-derived drug is the 
formation of DNA adducts. Cisplatin covalently binds to DNA via binding to 
specifically N7 position of adenine and guanine, causing DNA adduct formation 
[41]. The most important and frequent type of DNA adduct is 1,2-intrastand, which 
is occured by the replacement of Cl
-
 ions with purine atoms on adjacent bases 
(commonly guanine) atthe same DNA strand [42].  
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Following intrastrand DNA adducts, DNA damage recognition proteins become 
activated and functional to repair DNA. However, cisplatin cause distruption of the 
DNA repair mechanism therefore replication and transcription processes could not 
get repaired. Cisplatin-induced apoptotic induction is not the only reason for the 
breakdown of DNA repair mechanism, but also pro-apoptotic signals become active 
to initiate apoptosis [43]. 
Cisplatin-induced apoptotic machinery is triggeredby distinct death signals. 
According to the cisplatin treatment, DNA damage activates the ataxia telangiectasia 
mutated protein (ATM) and ATM and Rad3 related protein (ATR) kinases as an up-
stream target of p53. Then, ATR phosphorylate and activate p53 [44]. Following 
activation of p53, pro-apoptotic Bax translocated from cytosol into mitochondria, 
caspase 9 activation occurs by the release of cytochrome c from mitochondria into 
cytosol and finally activation of caspase 3 induce apoptosis [45].  
Cisplatin-mediated activation of MAPK pathway occurs via induction of 
extracellular signal-regulated kinase (ERK), stress-activated protein kinase 
(SAPK/JNK) and p38 protein. Activation of ERK has a role on phosphorylating and 
activating p53 protein [46]. 
Exposure of cells with cisplatin induces cell cycle arrest at S and G2/M phases via 
downregulation of specific cyclin-CDK complexes (Cyclin D1-CDK 4, Cyclin B1-
CDK 1) in these phasesand regulation of p21
Waf1/Cip1
also induce cell cycle arrest [47].  
However, cisplatin is the most common conventional drug to treat several types of 
cancer cells, the cytotoxicity and nephrotoxicity are main side effects of this drug. 
Therefore, new platinum-based drugs were discovered to decrease the side effects of 
cisplatin. Carboplatin is a less-toxic analogue that decreases the toxicity and 
nephrotoxicity, addition to that does not affect the tumor efficacy [48]. However, 
formation of DNA adduct by carboplatin is similar to the cisplatin structure, the rate 
of DNA adduct by carboplatin is approximately 10-fold slower than cisplatin. The 
survival rates of cisplatin and the analagoue carboplatin is comparable to that of 
ovarian cancer.The effect of cisplatin on apoptotic pathways are shown in Figure 1.2. 
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Figure 1.2 : Cisplatin induced apoptotic pathways, adapted from [40]. 
 
Cisplatin and carboplatin are good candidates for the treatement of different types of 
cancer cells over 40 years.  
Nowadays, cisplatin resistance gains importance. There are several factors for 
cisplatin resistance; reduced drug intake and accumulation into the cell,increased 
drug efflux, failure to maintain required dosage upon administration (cisplatin to 
DNA ratio maintenance in cells) or decrease platination of DNA and lack of cell 
death activation [49, 50].Decrease in the accumulation of cisplatin leads to 70-90% 
resistance in cancer cells [51]. In addition, downregulation of stress-activated MAPK 
family member proteins are related with the resistance of cisplatin [52]. Cisplatin-
induced DNA damage can successfully repair in cisplatin resistant cells via 
activation of nucleotide excision repair (NER) proteins [53].  
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1.2.2 Paclitaxel 
Paclitaxel is isolated from Taxusbrevifolia (Pacific yew tree) in 1971 [54]. It is an 
effective antineoplastic chemotherapeutic agent to induce apoptosis in breast, 
ovarian, prostate and cervical cancer cells. Paclitaxel is the member of microtubule 
inhibitors (MIs) family. MIs consist of microtubule polymerizing agents are 
commonly known as taxanes and depolymerizing agents that are vinca alkaloids 
[55].The structure of hydrophobic paclitaxel is shown in Figure 1.3. 
 
 
Figure 1.3 : The structure of paclitaxel, adapted from [54]. 
 
Cells are existed in well organized manner in their internal space, they interact with 
each other, transport, divide and grow and these mechanisms are occurred by 
cytoskeletal proteins which are intermediate filaments, actin filaments and 
microtubules. Microtubules arecyclindric cores and consist of heterodimer tubulin 
subunits that are α-tubulin and β-tubulin proteins. Both the association of α and β-
tubulin proteins form protofilaments in length and 13 of them form 
cyclindricmicrotubule formation with a diameter of 25 nm [56]. The orientation of 
these subunits allow the polarization of microtubule that β-tubulins occur at the top 
of microtubule and refer asplus end (+) and α-tubulins are existed at the bottom of 
microtubules and refer as minus end (-). The growth and shrinkage of subunits occur 
faster in plus end rather than minus end. They bind toGuanosine triphosphate(GTP) 
and the GTP binding form allows the assembly of tubulin subunits, however, the 
hydrolysis of GTP cause Guanosinediphosphate (GDP) formation and 
allowsdisassembly of tubulin heterodimers [57]. The assembly and disassembly of 
microtubules are shown in Figure 1.4. 
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Figure 1.4:The dynamic structure of microtubules, adapted from [56]. 
 
In healthy cells, assembly and disassembly of microtubules exist in a balanced 
manner, but chemotherapeutic agents are used to inhibit microtubule formation by 
the increase in polymerization or depolymerization of tubulin subunits. During the 
cell division process, mitotic spindle apparatus isformed by microtubules for the 
seperation of chromosomes to the poles and daughter cells [58]. Microtubules are 
responsible from the shape and movement of cells, localization of organelles in the 
cells and mitotic spindle formation during mitosis [59]. Tubulin subunits are 
disassembled during interphase but reassembles at mitosis phase to form the mitotic 
spindle that is responsible for segregating daughter chromosomes to the polesvia 
attaching plus end of microtubules to the chromosomes via kinetochore [60]. 
Anti-cancer chemotherapeutics are used to target microtubule formation and block 
mitosis. Colchicine or colcemid are drugs that inhibit microtubule polymerization but 
Taxolsare used for stabilization of microtubules rather than inhibition. As a 
microtubule-polymerizing agent (MTPA) paclitaxel binds to the N-terminal 31 
amino acids of beta-tubulin subunits reversibly, and causes retardation of 
microtubule depolymerization, blockage of mitotic spindle formation and mitotic 
arrest[54]. In addition, it inhibits microtubule reorganization process, leads to 
blockage of cell cycle and inhibition of cell proliferation. The mitotic blockage effect 
of paclitaxel causes accumulation in metaphase and anaphase and triggers mitotic 
arrest at G2/M phase [61, 62].  
Paclitaxel causes mitochondria-mediated apoptosis alone or combined treatment with 
other chemotherapeutic agents like cisplatin and doxorubicine. Activation of Bax and 
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Bak allows the translocation of these proteins into mitochondria and phosphorylation 
of Bcl-2 causes inactivation of this anti-apoptotic protein. Following these, releasing 
of cytochrome c and activation of caspase 9 and caspase 3 triggers the apoptotic 
machinery [63].It is determined in previous studies, paclitaxel has an effect to 
activate SAPK/JNK pathway via activation of Ras oncogene [64]. In addition MIs 
blocks the mitosis at cell cycle process, therefore paclitaxel has an inhibitory effect 
on G2/M transition and Cyclin B1 and CDK 1 protein complexes [65]. Intrinsic 
apoptotic machinery is activated during the paclitaxel-treatment process, pro-
apoptotic Bcl-2 family members are upregulated and anti-apoptotic proteins are 
phosphorylated and downregulated. The possible effects of paclitaxel treatment on 
apoptotic parameters and signaling pathways are shown in Figure1.5. 
 
 
Figure 1.5 : Paclitaxel-induced apoptotic and signaling pathways, adapted from [62]. 
 
Although, paclitaxel has several apoptotic functions, investigating the paclitaxel 
resistance will enlighten the drug treatment mechanism. Similar to resistance 
tocisplatin, increased drug efflux and upregulation of drug efflux transporter proteins 
lead to paclitaxel resistance [66]. Deficiency on p53 protein function and 
overexpression of Bcl-2 protein causes resistance to paclitaxel [67, 68]. In addition, 
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upregulation of Heat shock proteins, especially Hsp90, in acquired paclitaxel 
resistant MCF-7 breast cancer cells are related with increased survival rate of cancer 
cells [69]. 
1.2.3 Other chemotherapeutic agents and combinational treatment models 
Tamoxifen, the anti-estrogen chemotherapeutic, inhibits the binding or estrogen to 
ER and supress the initiation of gene expression. The non-steroidal anti-estrogen 
Tamoxifenhas been used since 1970s to treat breast cancer. It binds to estrogen 
receptor and inhibits the synthesis of estrogen in breast cells [70]. It is approved at 
1998 as a chemopreventative drug for women at high risk of breast cancer [71]. 
Trastuzumab (Herceptin) is a monoclonal antibody that is based on the binding of 
Herceptin toHer-2/neu (Human epidermal growth factor receptor-2) tyrosine kinase 
receptor. Her-2/neu receptor is the member of epidermal growth factor receptor 
(EGFR) family that enhances the proliferation of breast cancer cells. Herceptin is 
responsible for the binding of Her-2/neu receptor and inhibits the binding of EGFR 
to the Her-2/neu receptor [72, 73]. 
According to the mutations on BRCA1 and BRCA2 mutations, the risk of breast 
cancer is increased. To figure out the therapeutic applications on suppressing cancer 
development in BRCA1 or BRCA2-associated cancers, Poly (ADP-ribose) 
polymerase (PARP) inhibitiors are used alone and combination with platinum-based 
drugs such as; carboplatin or cisplatin. It is shown that combined treatment of PARP 
inhibitor and carboplatin or cisplatin is more significant for the treatment of BRCA1 
of BRCA2 mutated breast cancers [74]. 
HA14-1 is the Bcl-2 inhibitor that is performed to incude apoptosis in various cancer 
cell lines. It is used alone or combination with chemotherapeutic drugs such as; 
cisplatin to enhance the apoptosis machinery. Induction of apoptosis via HA14-1 
occurs by cytochrome c release, caspase3 and 9 activation and DNA damage [75]. 
This inhibitor is also effective on the induction of apoptosis in cisplatin resistant 
cancer cell lines [76]. 
1.3 Gene silencing strategy by small interfering RNAs 
Addition to classical chemotherapeutic drugs, novel potential target molecules gains 
importance to transiently silencing of specific gene expression for the treatment of 
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various cancer type. RNA interference (RNAi) is a post-transcriptional gene 
silencing technology for degredation of mRNA and downregulation of gene 
expression level [77]. The mechanism of gene silencing relies on the suppression of 
complementery double-stranded RNA (dsRNA) sequence by exogeneousdsRNA. 
The biological RNAi mechanism discovered in plants firstly[78], then 
Caenorhabditis elegans used as a model for gene silencing experiments [79].  
 
 
 
Figure 1.6:Formation of siRNA structure by RNAi machinery, adapted from [80]. 
 
The RNA silencing mechanism initiates with RNAse III endonuclease Dicer that is 
an enzyme for the cleavage of largerdsRNAs into small interfering RNAs (siRNAs) 
about 21-23 nucleotide in length with two nucleotide 3' overhangs. 
Then Dicer builds a complex with RNA-induced silencing complex (RISC), TAR-
RNA binding protein (TRBP) and Argonaute (Ago) family member protein on the 
dsRNA. This RISC complex unwound and separate the dsRNA into single-stranded 
RNA (ssRNA). This RISC comlex attached ssRNAmolecule is referred as active 
anti-sense strand and responsible for the degredation of complementary mRNA, 
which is referred as sense strand [80]. Active RISC-ssRNAcomlexis responsible for 
the targeting complementary mRNA molecule (sense strand) via base pairing and 
degredation of this mRNA in a sequence specific manner. Based on this, siRNA is a 
naturally occurred dsRNA molecule but artificial siRNAs about 21-23 nucleotide in 
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length are also available for silencing of gene expression [81]. siRNA mediated gene 
silencing occurs at translation process thefore, siRNA does not interact with DNA.  
siRNA-based treatment methods gains importantce as a novel approaches for the 
treatment of cancer, cardiovascular disease, genetic disorders, single nucleotide 
polymorphism, Alzheimer’s disease or viral disease [82-85].  
There are some points to take into consideration for choosing of exact siRNA such 
as; conserved sequences in gene, GC content, secondary structure, length (19-23 
nucleotides) and sequence of target mRNA are important points for designing 
appropriate siRNA [86]. The new therapeutic approach has several advantages such 
as; siRNA mediated gene silencing prevents the cytotoxicity from chemotherapeutic 
drugs and allows the functional analysis of genes.There are several siRNA-based 
drugs enter the clinical phase trials with the ability of silencing specific mRNA 
molecules in the cells. On the other hand, immune response might be one of the 
disadvantages of siRNA therapy such as;delivery of much siRNA molecules or 
longer siRNAs might recognized by immune system with different receptors and 
activation of immune system decrease the sequence specifity or degredes of siRNA 
[87, 88]. 
As an anionic, hydrophilic and membrane permeable characterization of siRNA, the 
delivery methods changes dependend upon the transfection time and cell type. 
Vector-mediated, lipid-based, polymer-mediated and physical delivery of siRNA are 
examples of different delivery methods.  
1.4 Apoptosis 
Apoptosis is a highly regulated programmed cell death mechanism that eliminates 
damaged cells in multicellular organisms to maintain the constant cell numbers. 
Australian scientist John Foxton Ross Kerr discovered this type of cell death at 1962 
[89]. Cancer and neurodegenerative diseases are related with deregulations or 
disruptions of apoptosis. Because of their uncontrolled cell proliferation functions, 
cancer cells are unable to go apoptosis. Elucidation of the molecular pathways of 
apoptosis is a fundamental process to transform the cancerous cells to apoptotic cells 
via effective chemotherapeutic agents.  
The important features of apoptosis are membrane blebbing, specialized membrane 
structure loss, cell shrinkage and nuclear condensation and fragmentation. Apoptotic 
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cells are phagocytosed by macrophages and neighbored cells without any release of 
cell content or inflammatory response [89]. Apoptosis occurs with by types of 
pathways that are death receptor-mediated or extrinsic pathway and mitochondria-
mediated or intrinsic pathway and these pathways connect with each other at this cell 
death process [90]. Apoptosis initiates with several stimuli such as; DNA damage, 
microtubule distruption, ER or mitochondrial membrane damage, UV light, 
generation of reactive oxygen species, ligation of death receptors on the cell 
membrane or withdrawal of growth factors. These stimuli are specific for the death 
receptor-mediated extrinsic or mitochondria-mediated intrinsic pathway of apoptosis. 
1.4.1 Death receptor-mediated extrinsic pathway 
Death receptors are transmembrane proteins and the most important death receptors 
areTNF family such as;TNF-R1 (CD120a), CD95 (APO-1/Fas)  and TNF-related 
apoptosis inducing ligand (TRAIL) that are; DR3, TRAIL-R1, TRAIL-R2 and DR6 
[91]. Death reseptors binds their specific ligands and death signals are transferred 
with adaptor proteins such as; FADD, CRADD and caspase 8 [92]. Binding of 
receptor to its specific ligand activated caspase 8 and caspase 8 activated caspase 3 
for the induction of apoptosis [93].   
1.4.2 Mitochondria-mediated intrinsic pathway 
The intrinsic pathway of apoptosis is proceeded by independently of receptor 
activation and occurs with activation of caspase cascade and Bcl-2 family proteins. 
Distruption of mitochondria membrane permeability is the major factor of intsinsic 
pathway of apoptosis. The anti-apoptotic or pro-apoptotic members of the Bcl-2 
family control the mitochondrial membrane permeabilization and release the pro-
apoptotic proteins such as cytochrome c, APAF-1 or SMAC from mitochondria into 
cytosol. Activation of effector caspases 3 and 7 through caspase 9 is an essential 
procees for mitochondria-mediated apoptosis [94]. 
Apoptosis occurs via interaction of death receptor and mitochondria-mediated 
apoptotic parameters that are caspases, Bcl-2 protein family, p53 and inhibitors of 
apoptosis.  
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1.4.2.1 Caspases 
Caspases are effectors and executioners of apoptosis and cleaves various target 
proteins. These aspartate-specific cysteine proteases have highly conserved domains. 
The cysteine (C) residues at their active sites of caspases cleave their substrate 
proteins after aspartic acid (Asp) residues.Caspases are divided in groups such as; 
caspase 1, 4, 5, and 12 are inflammatory caspases, caspase 3, 6 and 7 are effector 
caspases andcaspase 2, 8, 9, 10 are initiator caspases [95]. All caspases are 
constitutively expressed and synthesized as an inactive pro-caspases form 
(zymogens), then the proteolytic cleavage of pro-domain at aspartate residue of pro-
caspases alters the arrangement of caspase formation, seperates the large subunit 
from the small subunit and generates an active tetramer with two active sites. 
The most important initiator caspase is caspase 9. Caspase 9 has a role in 
mitochondria-mediated intrinsic pathway and forms a heterotrimeric complex with 
apoptosis protease activating factor 1 (APAF-1)and cytochrome c which are released 
from mitochondria via apoptotic stimulus [96]. APAF-1 is resided in the cytosol and 
according to apoptotic stimuli cytochrome c binds to this protein and causes a 
conformational change that leads to activation of pro-caspase 9[97]. This 
multisubunit complex (Caspase 9- APAF-1-Cytochrome c) is termed apoptosome.  
Following apoptosome formation, active caspase 9 binds the effector caspases 3 and 
7, and leads to cleavage their pro-domains and activation of these enzymes. Then, 
caspase 3 and 7cleave and activate other downstream caspases [98].  
Following apoptosome formation, the stress-induced intiatorcaspase 2 is released 
from mitochondria with caspase 9 and enhances the mitochondrial membrane 
permeabilization by promoting the translocation Bax from cytoplasm to 
mitochondria.  
Most important cellular substrates of caspases are nuclear proteins, therefore 
caspases cause nuclear fragmentation and distruption of cytoskeletal proteins. 
Nuclear lamins reside at the inner side of nuclear envelope and responsible for the 
maintaining of nucleus integrity and chromatin organization. Active form of caspase 
6 degrades lamin A, a specific form of nuclear lamins, causes chromatin 
condensation and apoptotic body formation. Addition to lamin proteins, the nuclear 
protein poly (ADP-ribose) polymerase (PARP) that is responsible for DNA repair 
and stability is cleaved by caspase 3 or caspase 7 from at DNA-binding domain and 
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generates DNA fragments. Cleavage of this protein is directly related with DNA 
fragmentation and apoptosis. 
IAP (inhibitor of apoptosis) family proteins that have ability to suppress both 
intrinsic and extrinsic apoptosis via binding directly to caspases also control 
caspases. The interaction inhibits the caspase activity and targets caspases for 
degredation or ubiquitination in proteasome. There are several members of IAP 
family that have different inhibiton functions such as; X-linked inhibitor of apoptosis 
protein (XIAP) prevents the activation of caspase 3, survivin binds to caspase 3 and 
caspase 7 and also increased in the mitotic spindle formation at the G2/M phase, c-
IAP1 and c-IAP2 directly inhibits caspase 3 and 7 [99]. 
1.4.2.2 Bcl-2 family members in apoptosis 
Bcl-2 protein was discovered at 1985 as an oncogene for the development of B cell 
non-Hodgkin’s lymphomas. The 26 kDa protein consists of threeBcl-2 
homology(BH) domains and inhibits apoptosis via blocking mitochondria membrane 
permeabilization [100]. Bcl-2 protein localizes at the outer membrane of 
mitochondria, endoplasmic reticulum and nucleus. There are at least 20 members of 
Bcl-2 family. They are subdivided into two functional groups; pro-apoptotics that 
promote cell death and anti-apoptotics that prevent cell death. 
An anti-apoptotic family member of Bcl-2 family, Bcl-2, Mcl-1, A1/Bfl-1, Bcl-W 
and Bcl-XL, inhibits apoptosis and promotes cell survival. Pro-apoptotic of Bcl-2 
family members inducecaspase activation and apoptosis that are divided into two 
subgroups. Both anti-apoptotic and pro-apoptotic Bcl-2 family members have 
conserved BH domains. Multidomain pro-apoptotic proteins (Bax, Bcl-Xs and Bak) 
have three BH domain (BH1, BH2 and BH3) that is required for apoptosis.BH3 pro-
apoptotic proteins (Bad, Bik, Bid, Noxa and Puma) have only one BH3 domain. 
Most of the Bcl-2 family members are related with mitochondria membrane and 
establish various interactions such as homodimerization or heterodimerization with 
each other [101]. The BH3-only pro-apoptotic proteins of Bcl-2 family are inactive 
in normal cells and they are regulated by the cell survival or cell death signals. 
Anti-apoptotic Bcl-2 family members keep multidomain pro-apoptotic Bcl-2 family 
proteins in inactive form as a heterodimer complex in normal cells. Once the 
activation of pro-apoptotic BH-3 only proteins occurs, they antagonize the anti-
apoptotic Bcl-2 family members and activate multidomain pro-apoptotic Bcl-2 
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family proteins and leads to apoptosis.Overexpressions of several genes enhance the 
survival activity of cells and development of cancer such as Bcl-2 family proteins; 
Bcl-2, Bcl-XL, Mcl-1 and Bag-1 or IAP family protein. Downregulation of these 
proteins using antisense oligonucleotides enhances sensitivity of apoptosis. 
One of the primary roles of Bcl-2 family members in the mitochondrial-mediated 
apoptosis is altering the mitochondrial membrane permeabilization and opening 
pores: Various apoptotic stimuli change the electrochemical gradient (Δψ) of the 
mitochondria membrane and open pores via the contribution of voltage dependent 
anion channel proteins (VDAC) at the contact sites of inner and outer mitochondrial 
membranes. These pores unbalance the ion gradient between the matrix and 
intermembrane space of mitochondria [102-104]. The matrix expands through the 
entry of water from intermembrane space. The other one is, releasing apoptotic 
proteins from mitochondria into cytosol such as cytochrome c and AIF (Apoptosis 
inducing factor) and activation of caspases occurs via Bcl-2 family members.In 
normal cells Bax (Bcl-2 associated X protein) resides in the cytoplasm in the inactive 
and folded form.  
According to apoptotic stimuli, Bax unfolds, translocates to outer membrane of 
mitochondria and multimerizes. Similar to Bax, Bak (Bcl-2 agonist killer) localizes 
at the outer membrane of mitochondria as a multimeric form. During apoptosis, Bax 
and Bak form oligomers at outer mitochondrial membrane and these formation leads 
to release of cytochrome c from mitochondria to the cytosol. Cytochrome c binds to 
APAF-1 and forms an apoptosome complex with caspase 9. And the initiator caspase 
9 triggers the activation of other effector caspases. The BH3-only proteins NOXA 
and PUMA are proapoptotic proteins that are expressed by p53 tumour suppressor 
protein. Following DNA damage and genotoxic stress, these proteins localizes at the 
outer membrane of mitochondria where they interact with anti-apoptotic Bcl-2 and 
Bcl-xLproteins and promotes to mitochondrial membrane permeabilization. 
According to the death receptor-mediated extrinsic apoptotic pathway, the death 
signal is transduced via adaptor protein caspase 8. Activation of caspase 8 leads to 
cleavage and activation of BID (BH3-interacting domain death agonist) protein. 
Truncated form of BID is translocated at the mitochondrial membrane and 
oligomerization of tBID enhances the mitochondrial membrane permeabilization. 
Therefore, BID is a connection between extrinsic and intrinsic apoptotic patways. 
The anti-apoptotic homologue of Bcl-2 is Bcl-XL  have 3 BH domain that promotes 
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cell survival but the splice variant, Bcl-Xslacks the BH1 and BH2 domain and acts as 
a pro-apoptotic protein. Bcl-XL has a role in opening small pores at the mitochondria 
membrane. Enhanced expression levels of Bcl-XL shows a resistance to 
chemotherapeutic drugs and enhances the malignancy of some cancer types such as; 
NSCLC [105, 106].The BH3-only protein BAD is an inhibitor of Bcl-XL and 
promotes chemotherapeutic agents-induced apoptosis.In addition to Bcl-2 family 
members mediated apoptosis, generally, most of the DNA damaging agents (UV 
radiation, chemotherapeutic agents, free radicals, hypoxia etc.) affect the cell in p53 
related apoptotic pathway. According to stress conditions, the total level and 
transcription activity of p53 is increased and this gene is responsible from apoptosis 
pathways. Genes that are responsible in the cell cycle regulation and apoptosis are 
regulated by p53, such as; in the intrinsic pathway of apoptosis, death receptor 
CD95/Fas/Apo-1, Bax, Bid, Apaf1, Noxa and Puma are positively regulated and Bcl-
2, Bcl-XL  and Survivin are negatively regulated by p53. In addition, the proto-
oncogene c-mycproduct promotes apoptosis in the presence of p53 [107]. 
The important molecules that have role in extrinsic and intrinsic pathways of 
apoptosis is shown in Figure 1.7. 
 
Figure 1.7:The extrinsic and intrinsic pathway of apoptosis, adapted from [90]. 
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1.5 The role of reactive oxygen species (ROS) generation in apoptosis 
mechanism 
Based on the reasons of cancer, radiation is an important factor for the formation of 
cancer. Ionizing radiation damages DNA directly or interacts with water molecules, 
generates ROS and causes DNA damage. The interaction of ionizing radiation with 
water generates three important ROS via three reactions. The three important ROS 
are shown in Figure 1.8. 
 
 
 
Figure 1.8: The generation of three important ROS in the cells, adapted from [108]. 
 
Hydroxyl radicals (•OH) as the most dangerous reactive species interact with 
molecules and removes e¯ from this molecule. Hydogen peroxide (H2O2) is less 
reactive than •OH but more dangerous to DNA compared with other free radicals. It 
leads to oxidation of bases in DNA and cause mutations. Superoxide radicals (O2•¯) 
are the least reactive compoundswithin ROS [108]. Although, ionizing radiation 
exogenously induces the ROS generation, endogenous cellular events also increase 
their generation. In mitochondria some products are generated via oxidative 
respiration and most of these products are useful for cells but few of them are toxic 
for the eukaryotic organisms as ROS. [109]. Differently from radiation-mediated 
three types of ROS generation, oxidative respiration producesonly O2•¯ radicals. 
ROS have damaging effect on DNA and DNA repair mechanism, and an increase in 
the lipid peroxidation due to reactive oxygen species leads membrane permeability 
loss and cell death [110]. In addition, increase in the generation of ROS cause loss of 
protein function and protein structure [111]. Anti-oxidants are classified as 
endogenous, natural and synthetic anti-oxidants that are beneficial for scavenging of 
ROS. Therefore, the balance between ROS and anti-oxidants is important for the 
regulation of the cell processes [112]. 
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1.6 Characterization of Bag-1 
Bag-1 (Bcl-2-associated anthanogene) gene, is located on human chromosome 9, 
band 17, contains 7 exons, encodes 3885 base pair long mRNA [113]. The 
multifunctional Bag-1 protein interacts with a wide range of cellular targets and 
regulates cell survival, signalling, metastasis, proliferation, and transcription 
mechanisms in the cells. 
Cells express several Bag-1 isoforms through alternate translation initiation of a 
single mRNA. The most abundant isoform, p36 Bag-1S, is translated from an AUG 
codon and is predominantly a cytoplasmic protein. The largest isoform, p50 Bag-1L, 
is translated from an upstream CUG codon and, consistent with the presence of a 
nuclear localization signal (NLS) within its NH2-terminal extension, resides within 
the cell nucleus. The other isoform, p46 Bag-1M, is generally expressed at low levels 
in human cells and is not detected in other species. Various domains have been 
recognized within Bag-1 isoforms, including a ULD and a COOH-terminal 
evolutionarily conserved BAG domain. Bag-1 protects cells from a wide range of 
apoptotic stimuli, including Fas, cytotoxic drugs, staurosporine, heat shock, and 
growth factor withdrawal [114]. 
1.6.1 Localization 
As mentioned above, three different isoforms localized differently in cytoplasm or 
nucleus. Bag-1L (p50) isoform has Nuclear Localization Signal (NLS) and it rezides 
in the nucleus, Bag-1M (p46) does not have NLS and it is partitions between nucleus 
and cytoplasm and Bag-1S lack NLS sequence and it is localized in cytoplasm[115]. 
The Bag-1L and Bag-1M isoforms intensely localized in nucleus in gastric 
carcinoma cells. However, Bag-1S isoform is localized in the cytoplasm perpetually 
[116]. 
1.6.2 The role of Bag-1 in cancer 
Bag-1 overexpression has an effective survival role in the development and response 
to several drugs in various cancer types such as breast, lung, prostate, tyroid and 
gastrointestinal cancer. Elevated levels of Bag-1 protein observed in breast cancer 
development and overexpression of cytoplasmic Bag-1 protein are associated with 
early-stage breast cancer and the nuclear forms of Bag-1 expression is related with 
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with improved survival in patients treated with hormonal therapy. According to the 
breast cancer outcomes, higher expression of Bag-1 and Bcl-2 were determined in 
colon carcinoma tissues but these overexexpressions were not observed in normal 
mproteins, Bag-1 has a role to inhibit apoptosis via MAPK cascade activating Ras, 
Raf-1, MEK, ERK signaling molecules.  
As mentioned above, mutations on tumor suppressor p53 gene was related with most 
of the cancer cases, and related to this overexpression Bag-1 has been observed in 
p53 mutant cancer cells and causes suppression of p53 mediated apoptosis [117]. 
1.6.3 Interaction partners of Bag-1 
The anti-apoptotic Bag-1 protein, which does not belong to Bcl-2 family, binds and 
interacts with the Bcl-2 protein and enhances the anti-apoptotic ability of Bcl-2 
protein.The Bag-1 COOH terminus is also required for interaction and activation of 
Raf-1, a serine-threonine kinase involved in cell survival and proliferation that 
provides an alternate potential mechanism by which Bag-1 might promote cell 
survival. Hsp70 and Raf-1 compete for binding to Bag-1, and high levels of Hsp70 
prevent activation of Raf-1 by Bag-1 in hamster fibroblasts, suggesting that 
growthand/or survival-promoting effects of Bag-1 may be mediated by activation of 
Raf-1-dependent mitogen-activated protein kinase pathways and negatively regulated 
by chaperone binding [115]. 
1.7 Polyamines 
Polyamines (PA) are organic cationic amine derivatives that are found in all 
eukaryotic organisms [118]. The main natural polyamines are Putrescine (Put), 
Spermidine (Spd) and Spermine (Spm) that responsible for regulation of cell growth, 
cell proliferation, cell differentiation, protein synthesis, development of cancer, DNA 
stabilization and apoptosis [119]. As PAs are found in all organisms and tissues in 
the cell they are also obtained from daily diet such as red meats, cheeses, fruits and 
vegetables [120]. Elevated levels of PAs or increases in PA synthesis are related with 
aberrant cell proliferation, cell survival, inflammation and development of cancer 
[121]. The PA metabolism is under control of several enzymes including; 
biosynthetic enzymesOrnithine Decarboxylase (ODC) and S-adenosylmethionine 
decarboxylase (AdoMetDC) or catabolic enzymes Spermidine/spermine-N
1
-
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acetyltransferase (SSAT),N
1
-acetyl polyamine oxidase (APAO) and Spermine 
oxidase (SMO). Put is produced by the decarboxylation of Ornithine by ODC in urea 
cycle. The diamine Put is a precursor for triamineSpd and tetraamineSpm production 
by additionaminopropyl groups to these PAs by Spermidine synthase and Spermine 
synthase enzymes [122]. 
Upregulation of ODC expression level or increase in ODC activity is found in 
various cancer types. Therefore, inhibition of ODC activity is usedas a potential 
cancer treatment model.Difluoromethylornithine (DFMO) is performed as 
chemopreventive agent to inhibit ODC expression and suppress the progression of 
cancer. DFMO as a specific ODC inhibitor can be used alone or in combination with 
other chemotherapeutic agents to treat cancer [123]. ODC is a transcriptional target 
of c-myc oncogene therefore, upregulation of ODC is resulted with the myc-
dependent cancer development [124]. 
For the treatment of cancer related with polyamine metabolism; although single 
enzyme inhibitors are used for down-regulating biosynthetic enzymes, polyamine 
analogues are also performed to up-regulate polyamine catabolism via induction of 
SSAT in several cancer cells [125]. SSAT is responsible for the regulation of 
intracellular polyamine homeostasis, the infflux and efflux of PAs. Induction of 
SSAT by polyamine analogues, chemotherapeutic agents, stress factors or 
toxinsacetylates Spd and Spm and leads to degreadation or efflux of Spd and Spm 
from intacellular space to extracellular area [126]. Therefore, upregulation of the 
expression level of SSAT causes induction of PA catabolism and leads to apoptosis. 
In addition, acetylated polyamines are used by APAO for the conversion of Spm to 
Spd and Put or Spd to Put via oxidation process. During this oxidation process, 
reactive oxygen species (ROS) generation increased by the production of hydrogen 
peroxide (H2O2) and increased levels of H2O2 production results with the increase in 
DNA-damage in cells [127].   
1.8 Aim of study 
Treatment of breast cancer has shown considerable developments in recent years by 
using chemotherapeutic agents alone or combination with other drugs or specific 
gene silencing approaches. Besides, drug resistance mechanism is an important 
factor for limiting successful outcome of the treatment. Drugs target are the cell 
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survival and apoptosis mechanisms in cancer cells. Cell survival and apoptosis are 
the two major pathways that Bag-1 is involved, however, the molecular details of 
these mechanisms and crosstalk between the pathways are not clear yet. In this study 
we aim to understand Bag-1’s involvement in the balance between apoptosis and 
survival.For this reason, we investigated the effect of anti-apoptotic Bag-1 protein 
expression level in the cisplatin or paclitaxel-induced apoptotosis and drug resistance 
mechanism. We target the induction of apoptosis via cisplatin or paclitaxel treatment 
and/or Bag-1 silencing and in contrast, we overexpressed Bag-1 protein to study its 
role in the drug resistant apoptotic pathway in MCF-7 cells. 
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2.  MATERIALS and METHODS 
2.1 Materials 
2.1.1 Equipments 
Equipments that are used in this study are listed in Table 2.1. 
Table 2.1 :Laboratory equipments used in this study 
Name of equipment Catalog No Supplier company 
Autoclave OTO32  Nüve 
Balance LE6202S Sartorius 
Centrifuge 5417R Eppendorf 
CO2 incubator EN 025  Nüve 
Deepfreeze 2041D  Arçelik 
Distilled water machine D56412 TKA-Pacific 
Electroporation apparatus Micro Pulger 165-
2100 
Bio-Rad 
Electrophoresis blot system Tetra-Cell 165-8000 Bio-Rad 
Electrophoresis transfer system Trans-Blot Turbo  
170-4155 
Bio-Rad 
Electrophoresis power supply PowerPac/Basic Bio-Rad 
Fluoremeter Fluoroskan Thermo Labsystems 
Freezer (-80°C) Ultra Low New Brunswick 
Haemocytometer Z359629 Sigma Aldrich 
High pressure liquid chromotograpy 
(HPLC) 
1200 series Agilent 
Ice machine AF80 Scotsman 
Invert microscop XDS-1B SOIF 
Invert fluoresencemicroscope 1X71 Olympus 
Laminar flow  51022515 Thermo Scientific 
Liquid nitrogen  Arpege 40 Air Liquid 
Magnetic stirrer SB162 Stuart/Prolab 
Mini spin C1301B-230V Labnet 
Micropipette (0.5l-10l) EH52836 Thermo Scientific 
Micropipette (2µl-20µl) CJ17240 Thermo Scientific 
Micropipette (20µl-200µl) EH46925 Thermo Scientific 
Micropipette(200µl-1000µl) T27274 Thermo Scientific 
Microplatereader 680  Bio-Rad 
MicroPulserelectroporator 165-2100 Bio-Rad 
pH meter N315 SEM/Mettler Toledo 
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PVDF Membrane 88518 Thermo Scientific 
Shaker SSL4 Stuart 
Spectrophotometer Ultraspec 2100 Biosciences 
Refrigrator 4260TMB Arçelik 
Rotator SRT9D Stuart/Prolab/Prolab 
Water bath BM 302 Nüve 
Vacuum machine 5305BH020683 Epperndorf 
Vortex SA8 Stuart/ProLab 
X-Ray Film 34090 Thermo Scientific 
2.1.2 Molecular biology kits 
Molecular biology kits that were used in this study are listed in Table 2.2. 
Table 2.2 : Molecular biology kits used in this study 
Name of kit Catalog No Supplier company 
Cell Death Elisa assay 11774425001 Roche 
ProteoJET Mammalian Cell Lysis 
Reagent  
K0301 Fermentas 
Complete mini EDTA-free Lysis Reagent 047199640001 Roche 
PhosSTOP 04906837001 Roche 
Quick Start Bradford Protein Assay Kit 500-0201 Bio-Rad 
Erase-It Background Eliminator 21065 Thermo 
Fugene HD Transfection kit 04709705001 Roche 
2.1.3 Chemicals, media components and antibodies 
Chemicals, media components and antibodies that were used in this study are shown 
in Table 2.3. 
Table 2.3 :Chemicals, media component and antibodies used in this study 
Name of chemicals Catalog No Supplier company 
Acetic acid  27225 Sigma Aldrich 
Acridine orange A1398,0025 AppliChem 
Acrylamide/bis-acrylamide (30%) A3699 Sigma Aldrich 
Ammonium persulfate (APS) A3678 Sigma Aldrich 
Ampicillin  11593-027 Invitrogen 
Bag-1 siRNA (h) sc-29211 Santa Cruz 
Benzoil chloride A4746 AppliChem 
Bromophenol blue  A2331,0025 AppliChem 
Bradford reagent  23200 Thermo Scientific 
BSA 500-0007 Bio-Rad 
Chloroform A2279 AppliChem 
Cisplatin 1911228 KoçakFarma 
CM-H2DCF-DA C6827 Invitrogen 
Coomassie brilliant blue  500-0006 Bio-Rad 
 DAPI D1306 Invitrogen 
Developer solution P7042 Kodak 
Diethylether 296082 Sigma Aldrich  
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DMSO D5879 Sigma Aldrich 
DTT D0632 Sigma Aldrich 
DiOC6 2129966 Fluka 
DMEM 41906-029 Invitrogen 
EDTA A3452 Sigma Aldrich 
Ethanol absolute 32221 Rieel-de Haen 
Ethidium bromide 46067 Fluka 
FBS P290310 Pan Biotech 
Fixer solution  P7167 Kodak 
Geneticin (G418) 10131-35 Invitrogen 
Glacial acetic acid 91190 Sigma Aldrich 
Glycine  A1067 AppliChem 
Hydrochloric acid (HCl) 1.00319 Merck 
Hydrogen peroxide K39218400838 Merck 
Isopropanol 24137 Riedel-de Haen 
Luminol A8511 Sigma Aldrich 
2-Mercaptoethanol S4805940517 Merck 
Methanol  24229 Sigma Aldrich 
MTT  M2003 Sigma Aldrich 
Sodium Chloride (NaCl) A2942 AppliChem 
Negative siRNA 1027280 Qiagen 
Non-fat dry milk  9999 Cell Signalling Technology 
Paclitaxel (Taxol) 1K00455 Bristol-Myers Squibb 
p-Coumaric Acid CP008 Sigma Aldrich 
Phosphate buffer saline (PBS) (10X) P04-53500 Pan Biotech 
Penicillin/Streptomycine P06-07100 Pan Biotech 
Propidium Iodide (PI) A2261 AppliChem 
Prestained Protein Ladder 26616 Thermo Scientific 
PVDF Membrane  ND1502993C Thermo Scientific 
Sodium dodecyl sulfate (SDS) A3452 AppliChem 
Transfection Reagent 133215657 Qiagen 
N,N,N′,N′- Tetra 
methylethylenediamine (TEMED) 
A1148 AppliChem 
Tricine  161-0713 Bio-Rad 
Tris Base  A2264 AppliChem 
Trolox 270-267-1100 Alexis Biochemicals 
Trypsin-EDTA (1X) 25200-056 Invitrogen 
Trypan Blue  T8154 Sigma Aldrich 
Tween-20  S4927784 802 Merck 
Vitamin E 460-019-6005 Alexis Biochemicals 
z-LEHD-FMK 550381 BD Biosciences 
z-VAD-FMK 550377 BD Biosciences 
Anti-apoptotic Bcl-2 family kit  99412 Cell Signalling Technology 
Apoptosis sampler kit 9915 Cell Signalling Technology 
Bag-1 antibody 3920 Cell Signalling Technology 
Cell cycle regulation antibody 
sampler kit 
9932 Cell Signalling Technology 
IAP family antibody sampler kit 97705 Cell Signalling Technology 
Loading control antibody sampler kit 5142 Cell Signalling Technology 
MAPK antibody sampler kit 99265 Cell Signalling Technology 
NOXA antibody  sc-22764 Santa Cruz 
ODC antibody sc-390366 Santa Cruz 
p53 antibody 2527 Cell Signalling Technology 
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Page ruler prestained protein ladder SM0671 Fermentas 
PAO antibody sc-166185 Santa Cruz 
Pro-apoptotic Bcl-2 family member  9942 Cell Signalling Technology 
X-Ray Film 34090 Thermo Scientific 
2.1.4 Buffers and solutions 
2.1.4.1 Buffers for protein isolation and electrophoresis 
10X PBS (Phosphate buffered saline) 
80 g NaCl, 2.25 g KCl, 23.27 g NA2HPO4.12H20 and 2.05 g KH2PO4 were 
dissolved in 1000 ml dH20, pH adjusted to 7.4 and autoclaved. 
10 X TBS (Tris buffered saline) 
87.7 g NaCl, 12, 1 g Tris, 4 ml HClwere dissolved in 1000 ml dH20 and pH was 
adjusted to 7.4. 
10X Running Buffer 
250 mM Tris base, 1.92 M glycine and 1% (w/v) SDS were dissolved in 500 ml 
dH2O and pH was adjusted to 8.5. 
10X Transfer Buffer 
250 mM Tris base and 1.92 M glycine were dissolved in 500 ml dH2O. 
Acrylamide/bis-acrylamide solution for SDS-PAGE gel electrophoresis 
Seperating gel solution: Acrylamide 46.5 g and bis-acrylamide 1,5 g were dissolved 
in 100 ml dH2O. 
Stacking gel solution: Acrylamide 48 g bis-acrylamide 1,5 g were dissolved in 100 
ml dH2O. 
5XLaemmli Buffer 
1 ml 1% bromophenol blue, 10 ml glycerol, 2 g SDS, 5 ml  β-mercaptoethanol were 
added to 4 ml 1.5 M Tris-HCl pH 6.8. 5 ml total solution was aliquated and stored in 
-20°C. 
Stripping buffer 
62.5 mM Tris-HCl and 2% SDS (w/v) were dissolved in 500 ml dH2O and pH was 
adjusted 6.7. Before to use 352 l -mercaptoetanolwas added for 50 ml of solution. 
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Bradford Solution 
To determine the concentration of total protein content, Bradford Solution was 
prepared with 25 mg Coomassie Brilliant Blue, 12.5 ml ethanol (95%), 25 ml 
aseticasid and 212.5 ml dH20.  
2.1.4.2 Cell culture solutions 
Growth medium 
Mammalian breast cancer cell line MCF-7 were cultured in DMEM supplemented 
with 10% FBS, 2 mM glutamine, 100 UI/ml penicillin/streptomycin, 4500 mg/L D-
Glucose, 110 mg/L Sodium Pyruvate. Cultures were maintained in 37 °C in a 
humidified 5% CO2 atmosphere.  
Freezing Media 
Cells were stored in freezing medium which was consist of 90% FBS and 10% 
DMSO at –80°C for 24  h and then were kept in liquid nitrogen. 
2.1.5 Bag-1 siRNA and plasmids 
Bag-1 siRNA 
Bag-1 human (h) specific siRNA purchased from Santa Cruz to silence Bag-1 gene 
expression at the translation process and knocked-down protein expression profile. 
Target sequence of Bag-1 siRNA (h) hassense: AAAGAACAGUCCACAGGAAGA 
and antisense: UCUUCCUGUGGACUGUUCUUUsequences. 
To optimize the non-cytotoxic dose of Bag-1 siRNA (Santa Cruz): transfection 
reagent (Qiagen) complex, various concentrations of Bag-1 siRNA (h) (0.25-1 g) 
and transfection reagent (1 g siRNA: 3 l Transfection reagent)  were performed 
according to the calculations in Table 2.4. In this study 0.4 g Bag-1 siRNA: 1.2 l 
transfection reagent complex was optimized for non-cytotoxic concentration and 
used in further experiments. 
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Table 2.4: Bag-1 siRNA values with pmol, l and g conversions and the 
transfection reagent ratio. 
 
 
Bag-1 plasmid  
The plasmid vector that included Bag-1L overexpression was obtained from from our 
laboratory. The plasmid of this vector construction was CS-L0198-M02 
fromOmcisLink Expression Clone. Then, Bag-1 human cDNA ORF Clone was 
inserted in pEZ-M02 vector after removing of stop codon and addition of a C-
terminal TAP (tandem affinity purification)-tag containing sequentially CBP 
(Calmodulin binding peptide)- TEV (tobacco etch virus protease)- Protein A from N 
to C terminus by Capital Biosciences. Whole plasmid size was about 7285 bp with 
the 1038 bp ORF length. Ampicillin was the antibiotic for this plasmid, and 
Geneticin used for selection of stable colonies. DH5 was the suitable bacterial 
strain for transformation. The construction of plasmid vector was shown in Figure 
2.1.  
 
 
Figure 2.1: Bag-1 pEZ-M02 vector construction structure. 
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2.2 Methods 
2.2.1 Cell Culture 
MCF-7 (HTB-22) human breast cancer cells were purchased from American Type 
Culture Collection (ATCC, USA), and maintained in DMEM (Gibco, USA) at 37 °C 
in a humidified 5 % CO2 incubator.  
For Bag-1 silencing, MCF-7 breast cancer cells were transfected with Bag-1 siRNA: 
Transfection Reagent complex. Following Bag-1 silencing for 48h, cells were 
exposed cisplatin dissolved in PBS or paclitaxel dissolved in ethanol. Non-silencing 
complexes were used as an internal transfection control.  
To produce stable Bag-1 overexpressed clones, MCF-7 cells were transfected with 
pEZ-M02 expression constuct. For transfection, MCF-7 cells were seeded to 6-well 
plates at 80% confluency. The transfection was carried out according to the FuGENE 
HD Transfection Reagent (Roche Applied Science, Germany) protocol. Cells were 
transfected with various concentrations (4,6,8 l) of FuGENE HD Transfection 
Reagent and 2 g of Bag-1 plasmid DNA. Selection of stable Bag-1 overexpressed 
cells were performed via treatment with Geneticin (G418) at 100-800 g/l rate.  
When MCF-7 wt, Bag-1 overexpressed and Bag-1 silenced cells were confluent 
about 80%, subculturing of cells was performed to a new passage number. Cells were 
treated with 1X trypsin-EDTA solution for 2-3 min and centrifuged at 1200 rpm for 
5 min.After removal of supernatant, FBS containing medium was added to pellet for 
inhibition of trypsin activity. Cells were counted with haemocytometer and passaged 
to new flask or seeded in petri dishes depending on the experimental process.  
2.2.2 MTT Cell Viability Assay 
MTT cell viability assay was performed for this purposes; to determine thecytotoxic 
efficiencies of cisplatin or paclitaxel treatment, optimization of non-cytotoxic Bag-1 
siRNA delivery method and concentration such as; liposome mediated or 
electroporated siRNA delivery, or investigate the effect of caspase inhibitors on 
relative cell viability with cisplatin or paclitaxel treatment.For all this different 
expreriments, cells were seeded at 1x10
4 
density in 96-well plates and treated with 
various concentrations of cisplatin and paclitaxel in time dependent manner or 
treated with different concentrations of Bag-1 siRNA for 48h. According to the 
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experimental time points, 5 mg/ml 3-4,5-Dimethyl-2-thiazolyl-2,5-diphenyl-2H-
tetrazolium bromide (MTT) was added  and cells were incubated at 37° C for 4h. 
After removal of MTT reagent included media, 100 ldimethylsulfoxide (DMSO) 
was added to each wells and incubated for 5 min at dark conditions. Absorbance was 
determined at 570 nm (A570) using amicroplate reader.  
2.2.3 Electroporation 
To confirm that Bag-1 siRNA was not cytotoxic to MCF-7 cells, both liposome 
mediated and electroporation method was performed. In order to perform 
electroporation procedure, approximately 1,5X10
6 
cells were trypsinized. After 
removal of supernatant, cells were washed with 1XPBS and centrfigued at 1200 rpm 
for 5 min. 1 ml DMEM- (FBS-, Penicillin/Streptomycine-) was added to pellet and 
mixed. Cell suspensiontransferred to 0.4 ml electroporation cuvettes and appropriate 
Bag-1 siRNA concentreationwas added. Elecroporation cuvettes were put in 
MicroPulser electroporation apparatus chamber Cells were electroporated at 250 V 
with 2 pulses of 10 msec. Then cells were seeded at 5X10
5
density in 60 mm plates. 
According to the experimental procedure chemotherapeutic agents or NS treatment 
was performed. 
2.2.4 Colony formation assay 
In order to understand the effect of Bag-1 siRNA electroporation delivery, cells were 
seeded at 600 cells per well in 6 well plates and incubated in the presence of absence 
Bag-1 siRNA and/or cisplatin or paclitaxel for 14 days. After this time period, media 
was removed and cells were washed with 1XPBS, fixed with methanol: aceticasid 
(3:1) for 5 min. After removal of fixing agent, cells were stained with 0.5% crystal 
violet in methanol for 15 min, then cells were washed by tap water, and the 
morphological images were taken under light microscopy. 
2.2.5 Morphological images by fluorescence microscopy 
Fluorescence microscopy imaged were taken to observe the morphological changes 
in MCF-7 wt, Bag-1 overexpressed or Bag-1 silenced cells against cisplatin or 
paclitaxel treatment and/or Bag-1 siRNA.  
Briefly, cells were seeded at 1x10
5
density in 12-well plates and treated with cisplatin 
or paclitaxel for 24 and 48 h and/or Bag-1 siRNA. Following incubation period of 
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cells, cells were stained with different types of dyes as shown in Table 2.5. 
Following their incubation period at 37 °C, the dye inclueded media was removed 
and 1XPBS was added to cells and visualized by fluorescent microscopy according 
ro their specific exitation and emission wavelengths. 
 
Table 2.5 :Staining procedures of specific dyes  
Dye Final concentraion Incubation time Ex/Em nm 
PI 5mg/ml 30 min Ex:536 nm/Em: 617nm 
DiOC6 4 nM 15 min Ex: 488 nm/Em: 525 nm 
DAPI 5 mg/ml 10 min Ex: 350 nm/ Em: 570 nm 
AO 5 mg/ml 10 min  Ex: 460 nm/Em: 650 nm 
AO/EB  10 mg/ml 30 min  Ex: 510 nm/ Em: 595 nm 
2.2.6 Fluoremetric analysis of staining procedures 
Cells were seeded at 1X10
5
density in 12-well plates and treated with cisplatin or 
paclitaxel for 24 and 48 h and/or Bag-1 siRNA. In order to evaluate mitochondrial 
membrane distruption (Δψm), cells were stained with DiOC6 for 10 min to 
determine ROS generation caused by chemotherapeutic agents, cells were stained 
with DCFH-DA for 5 min. Following incubation times of each dyes, cells were 
washed with 1XPBS, trypsinized and centifuged at 2000 rpm for 5 min. 200 l 
1XPBS was added to pellet and seperated into 96-well plates specialized for 
fluoremeter reading at 50 l or cell suspension with 4 replicates. Fluoremetric 
reading was performed according to the excitation and emission wavelength that was 
specific for each dye.  
2.2.7 Survival assay (Trypan Blue Dye Exclusion Assay) 
MCF-7 wt, Bag-1 overexpressed or Bag-1 silenced cells were seeded at 1X10
5
 
density per well in 6-well plates and treated with cisplatin (50 m) or paclitaxel (50 
nm) for 24, 48, 72 and 96 h. According to the time points, cells were counted by 
using 0.4% (w/v) trypan blue dye at 1:1 ratio. 10l cells were counted by dual-
chamber Neubauer haemocytometer.  
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2.2.8 Apoptosis determination (Cell Death ELISA Assay) 
MCF-7 wt, Bag-1 overexpressed and Bag-1 silenced cells were seeded at 1x10

 
density in 96-well plates and treated with various concentrations of cisplatin or 
paclitaxel and/or Bag-1 siRNA. Cytoplasmic histone-associated-DNA-fragments 
(mono- and oligonucleosomes) were determined according to manufacturer 
instructions by Cell Death Detection ELISA Plus kit (Roche Applied Science, 
Germany). The reaction was measured at 410 nm (Bio-Rad, USA). 
2.2.9 Flow cytometer 
MCF-7 wt and Bag-1 silenced cells were treated with 50 M cisplatin or 50 nM 
paclitaxel in time dependent manner (24, 48, 72 h). Cells were trypsinized, washed 
with 1XPBS, centrifuged at 2000 rpm for 5 min and fixed with 100% ethanol 
overnight at 4°C. Then cells were centrifuged again, supernant was removed and 
cells were stained with 10 l of 40 g/l PI with 50 ml of 20 mg/ml RNaseat 37 °C 
for 30 min. 10000 cells per sample was analysed by flow cytometer. The cell 
apoptosis was determined by BD FACSCalibur and data analyses was performed 
with CellQuest software. 
2.2.10 Immunoblotting analysis 
Cells were lysed on ice using ProteoJET Mammalian cell lysis reagent containing 
protease inhibitor. Cell lysates were centrifuged at 13.200 rpm for 20 min at 4 °C, 
and protein concentration was measured by Bradford Assay. Equal amounts of 
protein lysate was loaded on 10%- 12 % SDS-PAGE or  tricine gels and transfered to 
0,22 m or 0,45 m PVDF membranes (Thermo Scientific, Canada) by semi-dry 
electroblotting with Mini-transblot (Bio-Rad, USA). After blocking with milk 
containing 5% Tris-buffered Saline(TBS)-Tween 20 (MP Biomedicals, USA), 
membranes were incubated with primary antibodies Bag-1 (mouse),Bcl-2 (rabbit), 
Bcl-XL (rabbit), Bax (rabbit), Bak (rabbit), Bid (rabbit), Bad (rabbit), p53 (rabbit), 
Noxa (rabbit), Puma (mouse), Caspase-9 (rabbit), Caspase-7 (mouse), Caspase-8 
(mouse), Caspase-2 (mouse), PARP (rabbit), CDK 1 (rabbit), Cyclin B1 (rabbit), 
CDK  4 (mouse), p38 (rabbit), p44/42 (rabbit), SAPK/JNK (rabbit), -actin (rabbit) 
monoclonal antibodies (CellSignallingTechnology,USA) or PAO (rabbit), ODC 
(rabbit) polyclonal antibodies (Santa Cruz, USA) overnight at 4 °C and  anti-mouse 
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or anti-rabbit IgG-HRP secondary antibody overnight at 4 °C (Cell Signalling 
Technology, Beverly, USA). After washing with TBS-Tween 20, proteins were 
detected via Super Signal West Femto Luminol/Enhancer Solution (Thermo 
Scientific, Canada) and exposed to Hyperfilm-ECL (Amersham Pharmacia Biotech,). 
Densitometric analysis of immunoblots was performed using Adobe CS3 Photoshop 
and GraphPad Prism 6 and all proteins were quantified relative to the loading 
control. 
2.2.11 Measurement of intracellular polyamine content with High Pressure 
Liquid Chromatography (HPLC) 
Cells were seeded at 1X106 density at 60 mm plates and treated with cisplatin or 
paclitaxel or combination with Bag-1 siRNA. Then, cells were washed with 1X PBS 
twice and harvested. The pellet was treated with 50% tricholoroacetic acid (TCA) 
and centrifuged at 13,200 rpm for 20 min. According to the benzoylationmethod 1 ml 
Sodium hydroxide (NaOH) and 10 l benzoil chloride were added to the supernatant. 
Tubes were incubated at dark conditions for 20 minutes, then 1 ml 5M sodium 
chloride (NaCl) and 2 ml diethyl ether was added to tubes and vortex. The lower 
parts of the tubes were added to new tubes and chloroform was added. Tubes were 
incubated at room temperature under the hood for evaporation of chloroform, then 
500 l methyl alcohol was added and samples were analyzes by high pressure liquid 
chromatography (HPLC).  
2.2.12 Statistical Analysis 
All the experiments were statistically analyzed by two way ANOVA using GraphPad 
Prism version 6 for Windows, GraphPad Software (www.graphpad.com). Error bars 
in the graphs were generated using ± standard deviation (SD) values. Significant 
differences between means were determined in MTT/XTT Cell viability assay, 
Survival assay, Cell Cycle and apoptosis analysis, Quantitative Real Time PCR 
analysis, Polyamine analysis by Tukey’s multiple comparisons tests, Apoptotic Cell 
Death Elisa Assay was determined by Dunnet’s multiple comparision test, and 
Immunochemistry analysis was determined by Sidak’s multiple comparisons test and 
ROS generation was determined by Bonferonni’s multiple comparisions test. In all 
statistical analyses, a probability of p<0.05 was considered significant for all 
statistical analysis. 
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3.  RESULTS 
3.1 Identification the role of Bag-1 silencing on cisplatin or paclitaxel-induced 
apoptosis 
3.1.1 Cisplatin or paclitaxel decreased cell viability in MCF-7 cells 
In order to determine the cytotoxic effect of cisplatin or paclitaxel, MCF-7 cells were 
treated with cisplatin (0-75 M) or paclitaxel (0-75 nM) for 24 and 48 h. According 
to the MTT cell viability assay, the cytotoxic efficiency of cisplatin or paclitaxel 
treatment was increased in a dose and time dependent manner (Figure 3.1 a-b). For 
further experiments 50 M cisplatin or 50 nM paclitaxel was selected as IC50 values 
of each drug for evaluation of the functional role of Bag-1 in drug induced apoptosis 
(Figure 3.1 c). 
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Figure 3.1 :Cisplatin or paclitaxel decreased the cell viability in a dose and a time dependent 
manner. MCF-7 breast cancer cells were seeded at 1x10
4
 density and treated with various 
concentrations of cisplatin (0-75 μM) or paclitaxel (0-75 nM) for 24 and 48 h (a-b).  
Treatment of MCF-7 cells with 50 μM cisplatin or 50 nM paclitaxel for 24 h was determined 
as IC50 value (c). MTT cell viability assay was performed to determine the relative cell 
viability of cells treated with cisplatin or paclitaxel. The bar histograms represent the mean ± 
SD of four independent trials with at least four replicates. ((a) p<0.0001, (b) p<0.0001 (c) 
p<0.0001 each result was compared with the untreated control cells by using Tukey’s 
multiple comparison test).  
3.1.2 Cisplatin or paclitaxel decreased the expression level of Bag-1 isoforms in 
MCF-7 cells 
To understand the potential effect of cisplatin or paclitaxel on Bag-1 protein 
expression level, total protein isolation was performed following 50 M cisplatin or 
50 nM paclitaxel treatment at early (0-12 h) and late (24-72 h) time points in MCF-7 
cells (Figure 3.2). Itwas observed that three distinct isoforms of Bag-1 were 
differently affected from each drug. Bag-1S isoform as the most expressed isoform in 
MCF-7 cells and it wasupregulatedby 0.15 fold at 2 h cisplatin and 0.25 fold at 8 
h,then downregulated by 0.25 fold at 12 h cisplatintreatment. Further treatment of 
cisplatin (24 h, 36 h) led to an increase on Bag-1S expression profile by 0.1 and 0.36 
fold,then cisplatin caused a downregulation on Bag-1S expression at 48 h and 72 h 
treatments by 0.40 and 0.45 fold. Bag-1M isoform showed a stable expression profile 
at early time points of cisplatin treatment but downregulated at a range of 0.25- 0.4 
fold at late time points of cisplatin treatment. Exposure of cells with cisplatin later 
than 24 h caused significant downregulation on Bag-1L isoform (Figure 3.2 a, c). 
According to the paclitaxel treatment, while Bag-1S isoformshoweda stable 
expression profile at all time points, Bag-1S expression was upregulated by 0.45 fold 
at 36 h treatment. Bag-1 M isoform was upregulated at range of 0.25- 0.35 fold at 
early time points of paclitaxel treatment but, further treatment of paclitaxel abolished 
the expression level of Bag-1M. Bag-1L isoform isreferred as the least expressed 
isoform of Bag-1 protein in MCF-7 cells. Paclitaxel showed the downregulatory 
effect on Bag-1L isoform after 12 h treatment. Later treatment of paclitaxel abolished 
the expression level of Bag-1L isoform(Figure 3.2 b, d).We suggested that each 
drugs were effective to down-regulate Bag-1 expression level at late time points (36 
h, 48 h, 72 h) and paclitaxel was more efficent on Bag-1 downregulation compared 
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to cisplatin treatment in time dependent manner. (24, 36, 48 and 72 h) by 1.6, 0.75, 
1.9 and 1.1 fold. 
 
 
 
Figure 3.2: The expression level of Bag-1 was decreased according to the cisplatin (a) or 
paclitaxel (b) treatment in a time dependent manner. Following 50 M cisplatin or 50 nM 
paclitaxel treatment, total protein lysates were analyzed by immunoblotting assay. -actin 
was used as a loading control.The densitometry analysis of the Bag-1 protein expression 
level was measured by Image j (c).  
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3.1.3 Bag-1 siRNA was effective to down-regulate Bag-1 protein 
The efficiency of Bag-1 siRNA on Bag-1 protein expression level was investigated 
by MTT cell viability and immunoblotting assay (Figure 3.3). The non-cytotoxic 
concentration of Bag-1 siRNA which caused significant decrease on Bag-1 protein 
expression level, MCF-7 cells were transfected with Bag-1 siRNA and liposome 
mediatedtransfection reagent complex for 48 h. Bag-1 siRNA and transfection 
reagent ratios was calculated according to the manufacturer instructions which were 
shown in Materials and Methods 2.1.4.3 and Table 2.4.The most efficient silencing 
effect on all isoforms of Bag-1 was observed following 3 l Bag-1 siRNA and 1.2 l 
transfection reagent complex. This concentration of Bag-1 siRNA caused 20% loss 
in cell viability compared to control cells. However, higher concentrations of Bag-1 
siRNA were found more than 50% cytotoxic for MCF-7 cells, non-silencing siRNA 
did not exert any effect on cell viability decrease determined by MTT cell viability 
assay (Figure 3.3 a). Transfection of Bag-1 siRNA andtransfection reagent complex 
downregulated Bag-1 protein expression within 48 h was investigated by 
immunoblotting assay. Bag-1L, Bag-1M and Bag-1S isoforms were downregulated 
following Bag-1 silencing by 0.3, 0.6 and 0.8 fold. When transfection of Bag-1 
siRNA combined with cisplatin or paclitaxel for 24 h, Bag-1 protein expression 
profile was abolished (Figure 3.3 b). According to the densitometry analysis, three 
different isoform was downregulated by Bag-1 siRNA at a range of 0.2- 0.8 fold 
(Figure 3.3 c).  
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Figure 3.3: Bag-1 siRNA and transfection reagent complex concentration was optimized by 
MTT cell viability assay and immunoblotting. (a) MCF-7 cells were treated with various 
concentrations of Bag-1 siRNA (20-80 pmol) and transfection reagentfor 48 h. MTT cell 
viability assay was performed to determine the appropriate non-cytotoxic concentration of 
Bag-1 siRNA. Colums represent the means ± SD of two independent trials with at least four 
replicates (p<0.0001). (b) 3 μl siRNA and 1,2 μl transfection reagent complex was 
transfected to MCF cells for 48 h, and 50 μM cisplatin or 50 nM paclitaxel treatment was 
performed  for 24 h. The effect of Bag-1 siRNA with cisplatin or pacliaxel was determined 
by immunoblotting assay. The densitometry analysis of the Bag-1 protein expression level 
was measured by Image j (c).  
 
3.1.4 Transfection of Bag-1 siRNA via electroporation method displayed the 
same cell viability decrease comparing with lipid formulated chemical 
transfection 
Addition to lipid formulated chemical transfection of Bag-1 siRNA, electroporation, 
physical transfection method, was performed to deliver naked siRNA into MCF-7 
breast cancer cells. The effect of Bag-1 siRNA transfection via electroporation was 
investigated by different methods such as; MTT cell viability assay, clonogenic assay 
and immunoblotting assay. 
3.1.4.1 Electroporation of Bag-1 siRNA had the same cell viability decrease with 
lipid-formulated transfection 
In this experiment, 6x10
3
 cells/well were transfected with 3l Bag-1 siRNA or NS 
siRNA by high voltage pulses of electricity and seeded of 96-well plates. In order to 
understand the efficiency of electroporation based siRNA delivery in the cells, all 
results were compared to two different control groups; first control group was not 
electroporated and the other grouop was electroporated but witouth siRNA delivery. 
Then, we also transfected cells with NS siRNA via electroporation. As shown in 
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Figure 3.4 transfection of cells with Bag-1 siRNA by electroporation method caused 
moderate cytotoxicity by 20% compared to the control group. In addition, no 
significant difference was observed between experimental control groups. While 
cisplatin treatment of non-transfected cells decreased the cell viability by 53%, cell 
viability was further decreasedby 67% in Bag-1 silenced MCF-7 cells. Paclitaxel 
caused 40% cell viability decrease, alone and combination of Bag-1 siRNA enhanced 
the cell viability loss about by 55%. 
 
Figure 3.4: The effect of electroporation method on cell viability decrease of MCF-7 cells 
was investigated by MTT cell viability assay.6x10
3
 cells were transiently transfected with 3 
l Bag-1 siRNA or NS siRNA alone and cisplatin or paclitaxel treatment by electroporation 
method (250 V). Colums represent the means ± SD of two independent trials with at least 
four replicates. 
3.1.4.2 Inhibition of colony formation enhanced by Bag-1 siRNA transfection 
after cisplatin or paclitaxel treatment 
Clonogenic cell survival assay was performed to test the effects of Bag-1 siRNA in 
the presence of cisplatin or paclitaxel on cell viability, cell proliferation rate and 
inhibition of colony formation in MCF-7 cells. It was shown in Figure 3.5 Bag-1 
siRNA did not cause an inhibition of colony formation buttreatment of cells with 
cisplatin or paclitaxel not only decreased the colony numbersbut, also significantly 
reduced the expansion of colony formation of MCF-7 cells compared to untreated 
cells. The silencing of Bag-1 dramatically enhanced drug-induced colony formation 
and cell expansion in colonies. NS siRNA transfected cells demonstrated similar 
colony formation with the cells that were electroporated without NS siRNA or Bag-1 
siRNA.  
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Figure 3.5: Bag-1 siRNA decreased the colony formation of MCF-7 cells with the contribution of cisplatin or paclitaxel treatment. It was observed by 
clonogenic cell survival assay. 1x10
3
 cells were seeded at 6-well plates following electroporation of MCF-7 cells with Bag-1 siRNA or negative siRNA for 48 
h and treated with cisplatin or paclitaxel for 24 h. Cells that were plated without treatment of drugs or electroporation served as control cells. The plates were 
incubated at 37 °C for 14 days in DMEM and different colony formations were observed under a microscope via crystal violet staining. 
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3.1.5 Bag-1 siRNA enhanced the inhibitory effect of cisplatin or paclitaxel on 
cell proliferation 
Trypan blue dye exclusion assay is a common method to test the viability of cells 
depending on the cell membrane integrity. In this experiment, trypan blue dye 
exclusion assay was performed to determine the number of viable cells following 
drug treatment in MCF-7 wt and Bag-1 silenced cells. However, untreated parental 
cells displayed intact cell membrane thatwas not stained with trypan blue; apoptotic 
cells were stainedtrypan blue due to the damage of cell membrane. In Figure 
3.6MCF-7 cells were treated with cisplatin or paclitaxel in time dependent manner. 
In addition, cells were transfected with Bag-1 siRNA for 48 h, thentreated with 
cisplatin or paclitaxel for 24, 48 and 72 h. The untreated control cell number was 
exponentially increased started from 24 h by 5-fold within 72 h. Bag-1 siRNA 
transfected MCF-7 cell numbers were increased by 2-fold, this result suggested that 
Bag-1 siRNA had a suppressive role on cell proliferation rate. Treatment of cisplatin 
(Figure 3.6 a) or paclitaxel (Figure 3.6 b) decreased the viable cell number in a time 
dependent manner. Further reduction in viable cell numbers was observedafter the 
combination of each drug with Bag-1 siRNA transfection. Therefore, it is concluded 
that Bag-1 siRNA enhanced the suppression of cell proliferation rate compared to the 
drug treatment, alone. 
 
Figure 3.6: Bag-1 siRNA enhanced the inhibitory effect of cisplatin or paclitaxel on MCF-7 
cells proliferation rates.MCF-7 wt and Bag-1 silencedcells were seeded at 1x10
5
 density in 6-
well plates and treated with 50 M cisplatin (a) or 50 nM paclitaxel (b) for 24, 48, 72 h. 
According to the time points, cells counted each day for 3 days using trypan blue dye 
exclusion assay. Lines represent unstained viable cell numbers and the means ± SD of three 
independent trials with at least four replicates (p<0.0001). 
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3.1.6 Bag-1 siRNA enhanced the apoptotic potential of cisplatin or paclitaxel 
During the apoptosis process, different from necrosis, endonucleases became active, 
cleaved double stranded DNA at internucleosomal regions and generated mono- and 
oligonucleosomes. These DNA fragments consisted of 180 bp subunits and named 
‘DNA ladder’. To investigate apoptosis, cell death Elisa assay was performed. This 
experiment was associated with using monoclonal antibodies targeted histone 
proteins and fragmented DNA molecule. Binding of histones to the streptavidin 
coated plates and separation of naked, fragmented DNA was occurred during this 
process. According to the Figure 3.7 transfection of Bag-1 siRNA was effective to 
increase apoptosis by 1.3 fold. Treatment of cells with 15, 30, 50 m cisplatin for 24 
hled to an increase in DNA ladderingby 1, 1.2 and 1.3 fold compared with untreated 
control cells. Combination of various doses of cisplatin and Bag-1 siRNA enhanced 
apoptosis by 1.5, to 2.2 fold. 50M cisplatin which was the IC50 value of this drug 
increased apoptosis by 1.3 whereas, co-treatment of Bag-siRNA and cisplatin caused 
a 2.2 fold increase on apoptosis (Figure 3.7 a). Treatment of 15, 30, 50 nM paclitaxel 
led to an increase in the apoptotic profile by 1.2, 1.4, 1.6 fold, respectively. 
Combination of Bag-1 siRNA and increasing concentrations of paclitaxel enhanced 
apoptosis by a range of 2 to 2.3 fold. While, the IC50 value of paclitaxel (50 nM) 
increased apoptosis by 1.6 fold, Bag-1 silencing and paclitaxel treatment increased 
apoptosis by 2 fold (Figure 3.7 b). 
 
Figure 3.7: Bag-1 siRNA increased the apoptotic effect of cisplatin or paclitaxel in MCF-7 
cells. Cells were seeded at 1x10
4 
density in 96-well plates and treated with cisplatin (15- 50 
M) (a) or paclitaxel (15- 50 nM) (b) for 24 h. Bag-1 siRNA transfected to MCF-7 cells for 
48 h and treated with appropriate doses of cisplatin or paclitaxel. Colums represent ± SD of 
three independent trials with at least four replicates (p value of graphic (a)p=0.0393) and 
(b)p=0.0149). 
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3.1.7 Exposure of MCF-7 cells with cisplatin, paclitaxel or Bag-1 siRNA caused 
morphological changes as a result of apoptosis 
As it was mentioned before the most important features of apoptosis were DNA 
fragmentation, nuclear condensation, cell shrinkage, mitochondrial membrane 
permeabilization loss and blebbing. In order to demonstrate these signs of apoptosis, 
different fluorescence dyes were used in drug or Bag-1 siRNA treated MCF-7 cells, 
according to their specifity for different parts of the cell. 
3.1.7.1 Propidium iodidestaining 
DNA intercalating fluorogenic compound PIwas used to specify dead cells in the 
total cell population. Nuclear condensation and DNA fragmentation were occurred 
following the chemotherapeutic agent treatment in the cells. PI was unable to pass 
the intact membrane and according to apoptosis, it passed throught the membrane as 
a result of membrane integrity loss and bound to double stranded DNA fragments. 
As shown in Figure 3.8 MCF-7 breast cancer cells were treated with cisplatin or 
paclitaxel for 24 and 48 h. In addition, to understand the silencing of Bag-1, cells 
were transfected with Bag-1 siRNA for 48 h and treated with cisplatin or paclitaxel 
for 24 h. Treatment of cells with cisplatin or paclitaxel for 48 h increased the dead 
cell numbers (red stained) compared with 24 h treatment of each drug. Although, 
both drugs were used to increase dead cells; cisplatin treatment was found more 
effective than paclitaxel treatment. Bag-1 siRNA transfection caused a slight increase 
in dead cell number, but combination of cisplatin or paclitaxel with Bag-1 siRNA 
caused significant increase in cell death. Beside the enhancement on the dead cell 
number, it was observed that co-treatment of Bag-1 siRNA and cisplatin or paclitaxel 
caused nuclear condensation in MCF-7 breast cancer cells.  
3.1.7.2 DiOC6 staining 
Most of the chemotherapeutic agents induce apoptosis via distruption on 
mitochondrial memberane potential (MOMP). The fluorescent membrane dye 
DiOC6 (3,3'-dihexyloxacarbocyanide iodide) was used to observe the alternations on 
mitochondrial membrane function following drug treatment or siRNA transfection. 
DiOC6 translocates from the lipid bilayer cell membrane and stains mitochondria 
and endoplasmic reticulum. Therefore, staining of cells with DiOC6 identified the 
live cells and labeled mitochondria (green stained).Exposure drugs and/or Bag-1 
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siRNA reduced the DiOC6 uptake in the cell. Determination of MOMP loss 
following drug treatment in the presence or absence of Bag-1 siRNA in MCF-7 cells 
was observed under fluorescence microscopy and measured by fluoremeter (Figure 
3.9 a, b). Treatment of cells with cisplatin or paclitaxel caused the loss of MOMP in 
time dependent manner. Cisplatin increase MOMP loss by 60 % and 80 % at 24 h 
and 48 h treatment and paclitaxel was effective to induce MOMP loss by 50 % and 
75 % at 24 h and 48 h treatment.Although, transfection of cells with Bag-1 siRNA 
alone did not exert any significant effects on the changes MOMP; the co-treatment of 
Bag-1 siRNA further increased the MOMP loss after cisplatin by or paclitaxel 
treatment by 90 % in MCF-7 cells (Figure 3.9 b). These morphological changes were 
also confirmed by fluoremeter readings (excitation: 485 nm- emission: 538 nm).  
3.1.7.3 Acridine Orange staining 
The metachromatic, cationic and vital fluorescent dye acridine orange (AO) was used 
to identify apoptotic cells with specific binding properties to nucleic acids in the cell. 
Acridine orange is a cell-permeable dye that has affinity to bind to single-strand 
DNA, double-strand DNA and single-strand RNA. The intact nuclei were shown as 
bright green by binding of AO to ds-DNA. In addition, cells were shown as red due 
to the binding of AO to ss-DNA or RNA. Besides its binding reactions to nucleic 
acid molecules, it provided the specification of apoptotic cells with their low pH 
conditions as an orange like appearance and also some autophagic conditions formed 
lysosomic vacuoles in the cell. As it was observed in Figure 3.10 the untreated 
parental cells and Bag-1 siRNA transfected cells were shown in bright green due to 
their intact nucleus. Exposure of cells with cisplatin or paclitaxel for 24 h caused 
membrane distruption and nuclear condensation as theywere shownred dots in the 
cell.Longer exposure of cells with these drugs for 48 h caused late apoptotic signs 
including low acidic conditions, increased nuclear condensation and formation of 
lysosomic compounds. Exposure of Bag-1 silenced cells to cisplatin or paclitaxel 
further enhanced the formation of lysosomic compound formation and membrane 
disruption as they were shown as small green particles in the cell and red dots around 
the nucleus. 
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3.1.7.4 Acridine orange (AO)/ ethidium bromide (EB) staining 
Determination of apoptosis was also performed with double staining of AO and EB 
that were specific to different parts of the cell and determined distinct apoptotic signs 
characterictic to nucleat alternations. As it was mentioned above, viable and non-
apoptotic cells were shown green and apoptotic or autophagic cells were shown 
orange or red as they stained with AO. In addition, AO staining performed with 
ethidium bromide (EB) to differentiate early apoptotic, late apoptotic, autophagic and 
necrotic cells. The most important difference between apoptotic and necrotic cells 
was apoptotic cells had normal nuclear structure with a fragmented DNA. EB was an 
intercalating agent of DNA and specified to display the late apoptosis including 
membrane distruption and nuclear condensation in the cell. It was used to specify the 
late apoptotic and highly membrane distrupted cells. As shown in Figure 3.11, 
exposure of cells to each drug caused an increase in membrane disruption and 
formation of lysosomic vacuoles comparedto untreated control cells. Bag-1 siRNA 
transfection caused further increasein nuclear membrane disruption and DNA 
fragmentationwhich are the signs of late apoptosis. 
3.1.7.5 DAPI staining 
DAPI(4',6-diamidino-2-phenylindole) is a DNA specific nucleic acid stain that binds 
to A=T rich regions in DNA and excited blue fluorescence. According to apoptosis, 
cell membrane loss was enhanced and the uptake and fluorescence of DAPI was 
increased. Addition to that, non-apoptotic cells were shown as light blue as intact 
nucleus and nuclear membrane, apoptotic cells showed as fragmented bright blue due 
to nuclear fragmentation, condensation and formation of nuclear bodies. As observed 
in Figure 3.12 untreated cells did not show any DAPI staining due to their intact 
nuclear membrane, but stained cells were determined in Bag-1 silenced MCF-7 cells. 
Treatment of cells with cisplatin or paclitaxel in time dependent manner caused an 
increase in DAPI stained cell number. Silencing of Bag-1 transiently in the presence 
of cisplatin or paclitaxel caused a significant increase on DAPI staining due to the 
increased uptake of DAPI through the damaged plasma and nuclear membrane 
(Figure 3.12 a). Based on the counting of DAPI stained cell numbers indifferent 
conditions, the bar graph was drawn. This graph was provided the quantitative 
analyses of the fluorescence microscopy images. Untreated control cells did not 
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show DAPI staining but exposure of cisplatin increased DAPI stained cell number by 
40 and 74 cells at 24 h and 48 h treatment. Similar to cisplatin, paclitaxel enhanced 
DAPI stained cell number at a range 36 to 49 cells in a time dependent manner. 
Transfection of cells with Bag-1 siRNA increased DAPI stained cell number to 11 
cells to compare with nontransfected control cells. Combined treatment of cisplatin 
or paclitaxel in the presence of Bag-1 siRNA enhanced DAPI stained cell number 
about 110 cells to compare with parental control cells (Figure 3.12 b). 
.
50 
 
-
C
is
p
la
ti
n
P
a
cl
it
a
x
el
24 h 48 h Bag-1 siRNA +
Bag-1 siRNA -
 
 
Figure 3.8: The effect of chemotherapeutic agents and silencing of Bag-1 on apoptosis was observed with nuclear condensation by PI staining.Cells were 
treated with cisplatin or paclitaxel in time dependent manner and transfected with Bag-1 siRNA for 48 h. Apoptotic cells were determined as red dots by PI 
staining. Images were taken at 200x expansion of cells.   
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Figure 3.9: Determination of MOMP was performed following cisplatin, paclitaxel or Bag-1 siRNA treatment in MCF-7 cells. Cells were treated with 
cisplatin or paclitaxel in time dependent manner and transfected with Bag-1 siRNA for 48 h. The loss of MOMP observed by DiOC6 staining (b) and measured 
by fluoremeter (p<0.0001) (c) (ex:485 nm, em:538 nm). Images were taken at 200x expansion of cells. 
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Figure 3.10: Determination of nuclear condensation and lysosomic compounds as the signs of apoptosis was performed with AO staining.Cells were treated 
with cisplatin or paclitaxel in time dependent manner and transfected with Bag-1 siRNA for 48 h. Images were taken at 200x expansion of cells. 
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Figure 3.11: Determination of the effect of cisplatin, paclitaxel or Bag-1 siRNA on the apoptosis mechanism was observed via AO/EB staining. Intact nucleus 
determined viable cells, red-orange like appearance of cell identified early apoptotic, lysosomic vacuoles presented early apoptotic or autophagic and red dots 
specified the DNA fragmentation as the late apoptosis. Images were taken at 400x expansion of cells. 
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Figure 3.12: Determination the effect of drugs and Bag-1 silencing on apoptosis was observed via DAPI staining. Cells were treated with cisplatin or 
paclitaxel in time dependent manner and Bag-1 siRNA transfection was performed for 48 h. Bright blue dots were determined the DAPI stained apoptotic 
cells by fluorescence microscopy (a). DAPI stained cells were counted in equal size images from different conditions and the bar graph was drawn 
(p<0.0001)(b).Images were taken at 200x expansion of cells. 
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3.1.8 Bag-1 silencing further enhanced the accumulation of apoptototic cells at 
sub-G1 phase 
In order to analyze the effect of chemotherapeutic agents or Bag-1 siRNA on cell 
cycle and apoptosis, we measure the size, the volume and the percentage of apoptotic 
nuclei by flow cytometry with PI staining. This approach determined the apoptotic 
cells in G1, S and G2/M phases depending on the fragmented DNA. As it was 
mentioned above, PI was bound to the DNA of apoptotic cells due to their disrupted 
membrane integrity and during the apoptotic process endonucleases cleaved the 
whole DNA molecule into small fragments (180 bp) and cell became hypodiploid 
which means less amount of DNA content in the cell. Accumulation of these 
fragments caused the cell cycle disruption or arrest and sub-G1 phase exhibited the 
membrane disrupted hypodiploid apoptotic cell accumulation.  
Apoptotic function of Bag-1 siRNA alone and combination with cisplatin or 
paclitaxel in MCF-7 breast cancer cells was detected by the use of flow cytometry 
with PI staining. The results revealed that the sub-G1 population was 3,06% for 
untreated parental MCF-7 cells and 2,06% for Bag-1 silenced cells. The sub-G1 
population was 7,57% for 24h treatment of cisplatin. However, combination of 
cisplatin displayed a significant increase in the accumulation in sub-G1 by 31,82% . 
The sub-G1 population was 5,9% for 24h treatment of paclitaxel. Co-treatment of 
Bag-1 siRNA with paclitaxel further enhanced the accumulation of apoptotic cell 
population in sub-G1 to 24,32%. 
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Figure 3.13: Determination of the role Bag-1 silencing on cisplatin or paclitaxel-induced 
apoptosis was performed by flow cytometry with PI staining. Cells were treated with drugs 
in time dependent manner and transfected with Bag-1 siRNA alone or co-treated with 
cisplatin or paclitaxel, then fixed with 70% ethanol and stained with PI.Determination the 
effect of Bag-1 siRNA and cisplatin on cell cycle (p<0.0001) (b).The effect of Bag-1 siRNA 
and paclitaxel on cell cycle (p<0.0001)(c). 
3.2 Determination the additive effect of Bag-1 silencing by investigating 
apoptotic parameters in cisplatin or paclitaxel-induced apoptosis 
3.2.1 Silencing of Bag-1 modulated the expression level of Bcl-2 family member 
proteins in cisplatin or paclitaxel-induced apoptosis 
In order to investigate the role of time dependent cisplatin or paclitaxel treatment 
and/ortransfection of Bag-1 siRNA in drug-induced apoptosis, the expression 
profiles of Bcl-2 family members in MCF-7 cells were investigated by 
immunoblotting assay (Figure 3.14). The altered expression levels of pro-apoptotic 
and anti-apoptotic members of Bcl-2 family were investigated in cisplatin or 
paclitaxel treated MCF-7 wt and Bag-1 silenced cells.  
Exposure of cells with cisplatin enhanced the cleavage of anti-apoptotic Bcl-2protein 
within 36 h treatment by 0.8 fold but further treatment of cisplatin caused 
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downregulation of full Bcl-2 protein expression level by 0.6 fold. Paclitaxel 
downregulated the expression of Bcl-2 protein in a time dependent manner at a range 
between 0.3- 0.55 fold. Transiently transfection of Bag-1 siRNA downregulated the 
Bcl-2 expression alone by 0.15 fold and the combined treatment of cisplatin and 
Bag-1 siRNA caused further downregulation by 0.5 fold.In addition, combination of 
Bag-1 siRNA and paclitaxel treatment abolished the Bcl-2 expression level. 
Cisplatin caused downregulation on the anti-apoptotic Bcl-XL for 24 h and 48 h 
treatment and abolished the expression profile ofBcl-XL at 72 h treatment. In 
contrast, paclitaxel was not efficient to down-regulate Bcl-XL protein through 48 h 
treatment but 72 h treatment decreased the expression level of Bcl-XL. Transfection 
of Bag-1 siRNA alone did not down-regulate Bcl-XL expression level, but combined 
treatment of Bag-1 siRNA with cisplatin or paclitaxel significantly reduced the 
expression level of Bcl-XL(Figure 3.14 a-b). 
The pro-apoptoticBaxexpression level was upregulated by 0.3-0.8 fold in a time 
dependent cisplatin treatment. Paclitaxel caused upregulation of Bax-2 protein by 1 
fold at 24 h but later treatment of paclitaxel cause downregulation about 0.7 fold at 
36 h and 72 h treatment. Bag-1 siRNA caused a significant upregulation on Bax 
protein by 5 fold comparing with untransfected control cells, but further upregulation 
was observed in combined treatment of Bag-1 siRNA and cisplatin or paclitaxel 
about 6 fold.  
However, untreated parental cells did not show the pro-apoptotic Bakexpression, 24 
h cisplatin treatment significantlyupregulatedBak expression by 4 fold and further 
treatments of this drug caused 3 fold upregulation on Bak expression level. Paclitaxel 
treatment upregulated Bak expression by 2 fold at 24 h treatment and later treatments 
of paclitaxel upregulated Bak expression by 1.5 fold. Bag-1 siRNA led to an 
upregulationon Bak expression alone and combination with cisplatin or paclitaxelat a 
range between 2- 2.5 fold . 
The expression level of pro-apoptotic Bidprotein was upregulated in atime dependent 
manner of cisplatin treatment by 2 to 3 fold, and paclitaxel treatement showed 
similar time dependent upregulation at a range of 3 to 4 fold on Bid expression 
profile. While Bag-1 siRNA caused an upregulation on Bid expression by 3 fold, 
Bag-1 siRNA combined cisplatin treatment caused a downregulation by 0.25 fold to 
compare with untransfected control cells. Treatment of paclitaxel in the presence of 
Bag-1 siRNA upregulated Bid expression by 2 fold to compare with parental cells.  
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Bad expression profile showed the upregulation in a time dependent cisplatin 
treatment at a range between 0.7- 2.3 fold and paclitaxel showed a similar time 
dependent upregulation on Bid expression at a range between 4- 5.5 fold. Bag-1 
siRNA upregulated Bad expression by 3 fold to compare with untransfected control 
cells. Combined treatment of cisplatin or paclitaxel and Bag-1 siRNA showed 3 and 
2.5 fold upregulation on Bad expression to compare with untransfected control 
cells(Figure 3.14 c-d).  
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Figure 3.14: Cisplatin or paclitaxel induced apoptosis and/or Bag-1 siRNA via modulating 
Bcl-2 family members. Cells were seeded at 1x10
6
density in 60 mm plates and treated with 
cisplatin or paclitaxel for 24 h. Bag-1 siRNA was transfected to MCF-7 cells for 48 h and the 
IC50 value of cisplatin or paclitaxel was performed to Bag-1 silenced MCF-7 cells. A total 20 
g of protein lysate was loaded in 12% SDS page and Tris-Tricine gel. Anti-apoptotic 
members of Bcl-2 family (a, b) and pro-apoptotic members of Bcl-2 family (c,d) was 
observed by immunoblotting assay. β-actin was performed as a loading control. 
3.2.2 Silencing of Bag-1 altered the expression level of p53 family member 
proteins in cisplatin or paclitaxel-induced apoptosis 
To understand the functional role of time dependent cisplatin or paclitaxel treatment 
in the presence or absence of Bag-1 siRNA in drug-induced apoptosis, the expression 
levels of p53 family members were investigated by immunoblotting assay (Figure 
3.15).  
It was observed that control cells exerted p53 expression and cisplatin 
upregulatedp53 protein expression level in a time dependent manner by 1.5 fold. 
Treatment of cells with paclitaxel for 24 h showed the highest upregulation on p53 
expression at 2 fold but, 36 h and 72 h treatment of paclitaxel caused 0.25 and 0.75 
fold upregulation. Bag-1 siRNA transfection alone caused 0.9 fold upregulation and 
combination with cisplatin or paclitaxel enhanced the p53 upregulation by 1.1 fold. 
Similar to p53 expression in control cells, untreated parental cells also showed Noxa 
expression and cisplatin or paclitaxel treatment further increased this expression 
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profile in a time dependent manner at a range of 1.3 to 1.5 fold. Bag-1 siRNA 
transfected cells upregulatedNoxa expression by 1.3 fold to compare with control 
cells and cisplatin treatment following Bag-1 siRNA transfection further upregulated 
this expression level by 1.7 fold. However, combined treatment of Bag-1 siRNA and 
paclitaxel was not effective as cisplatin treatment to upregulateNoxa expression in 
MCF-7 cells as it was shown the upregulation rate of 0.25 fold.  
Puma is a p53 upregulated modulator of apoptosis that serve as a target of tumor 
suppressor p53 gene. It consisted of 2 isoforms  and  to induce apoptosis. 
Untreated control cells showed full Puma expression and while, treatment of cells 
with 24 h cisplatin upregulated both  and isoforms by 0.7 and 1.4 fold, 36 h 
cisplatin treatment upregulated only isoform by 1 fold and 72 h treatment of 
cisplatin upregulated only isoform expression level by 2 fold. Treatment of cells 
with paclitaxel showed stable expression profile of and  isoforms but later 
treatments caused a downregulation at 36 h by 0.8 fold. Bag-1siRNA highly 
upregulated the isoform by 4 fold and showed slight upregulation of  isoform by 
0.3 foldof Puma protein. However, combination of Bag-1 siRNA and cisplatin did 
not show a significant upregulation on Puma protein expression, paclitaxel treatment 
was more effective to upregulate both isoforms of Puma by 0.8 fold increase for  
isoform and 2.5 fold increase for isoform. 
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Figure 3.15: Cisplatin or paclitaxel induced apoptosis and/or Bag-1 siRNA via modulating 
p53 family members. Cells were seeded at 1x10
6
density in 60 mm plates and treated with 
cisplatin or paclitaxel for 24 h. Bag-1 siRNA was transfected to MCF-7 cells for 48 h and the 
IC50 value of cisplatin or paclitaxel was performed to Bag-1 silenced MCF-7 cells (c). A total 
20 g of protein lysate was loaded in 12% SDS page and Tris-Tricine gel. β-actin was 
performed as a loading control. 
3.2.3 Investigation cisplatin or paclitaxel-induced apoptosis in MCF-7 wt and 
Bag-1 silenced cells depended on caspase dependency 
3.2.3.1 Investigation the role of cisplatin or paclitaxel on the expression levels of 
caspases in MCF-7 wt and Bag-1 silenced cells 
In order to understand the cisplatin or paclitaxel and/or Bag-1 siRNA-induced 
apoptosis pathways, the expression levels of caspases and PARP protein were 
investigated by immunoblotting assay (Figure 3.16). Caspase9 is a member of 
initiator caspases and during apoptotic process cytochrome c is released from 
mitochondria and forms a complex with pro-caspase 9 and Apaf-1 called 
‘apoptosome’. According to apoptosome formation, pro-caspase 9 is cleaved and is 
considered as a sign of apoptosis. Caspase9 was observed as its full form in control 
cells but cleaved due tocisplatin or paclitaxel treatments in a time dependent manner. 
Cisplatin caused downregulation of full form of caspase 9 by 0.65-fold within 72 h 
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treatment, in contrast cisplatin upregulated cleaved form of caspase 9 by 4-fold at 24 
h treatment and by 3- fold at later treatment. Paclitaxel downregulated full form of 
caspase 9 by 0.3 fold within 72 h treatment to compare with untreated control cells, 
and upregulated cleaved form at a range between 1.2 and 1.7 in a time dependent 
manner. Silencing of Bag-1 led to cleavage of caspase-9 but the short fragment of 
this protein was not observed.In addition, cisplatin or paclitaxel treatments following 
Bag-1 silencing enhanced cleavage of caspase-9 by 1.5 and 1.2-foldin MCF-7 cells.  
Caspase7 is one of the effector caspases and it is activated during apoptosis via 
upstream caspases and according to the caspase cascade.Caspase7 cleaves and 
activates downstream caspases and other proteins such as PARP. While, untreated 
control cells showed a full caspase7 expression profile by 1.3-fold in a time 
dependent manner, cisplatin enhanced cleavage of this protein by 2-fold within 72 h 
treatment. Paclitaxel was also effective to enhance cleavage of caspase 7 by 0.8, 2 
and 1.5-fold at 24, 36 and 72 h treament. Exposure of cisplatin or paclitaxel in the 
presence of Bag-1 siRNA downregulated full caspase 7 form by 0.5 fold, and 
upregulated its cleaved form by 2.6- fold in cisplatin and 4.5- fold in paclitaxel 
treatment.  
Upregulation in caspase2 expression level is one of the most important signs of 
apoptosis sincecaspase 2 is responsible as a upstream regulator for releasing of 
cytochrome c from mitochondria in DNA damage-induced apoptotic pathway. 
Caspase2 also is mentionedin death receptor- mediated apoptotic pathway. In 
untreated control cells, caspase2 expression did not observe but cisplatin upregulated 
its expression by 4-fold and paclitaxel upregulated its expression by 2-fold in a time 
dependent manner. Bag-1 siRNA was effective to upregulatecaspase2 activation by 
3-fold alone but combination with cisplatin or paclitaxel significantly 
upregulatedcaspase2 expression level by 4-fold.  
Poly ADP-ribose polymerase (PARP) is a nuclaer protein that is responsible for 
apoptosis and DNA repair mechanisms. Through the apoptotic machinery, PARP is 
cleaved at different sites via caspase dependently or independently. Although, 24 h 
and 36 h treatment of cisplatin led to cleavage of PARP by 1.55 and 1.95-fold, 72 h 
treatment caused1.7-fold PARP cleavage. In addition, 36 h and 72 h paclitaxel 
treatment significantly upregulated PARP cleavage by 2.2 and 2.5-fold in MCF-7 
cells. Silencing of Bag-1 did not significantly cause PARP cleavage but combined 
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treatment of cisplatin or paclitaxel with Bag-1 siRNA highly upregulatedthe PARP 
cleavage by 2.25 and 3-fold (Figure 3.16). 
 
 
 
Figure 3.16: Silencing of Bag-1 modulates cisplatin or paclitaxel induced apoptosis via 
caspases and PARP. Cells were seeded at 1X10
6
density in 60 mm plates and treated with 
cisplatin or paclitaxel for 24 h. Bag-1 siRNA was transfected to MCF-7 cells for 48 h and the 
IC50 value of cisplatin or paclitaxel was performed to Bag-1 silenced MCF-7 cells. Atotal 20 
g of protein lysate was loaded in 12% SDS page and Tris-Tricine gel.  
64 
 
3.2.3.2 Investigation the dependency to activation of caspases in cisplatin or 
paclitaxel treated MCF-7 cells 
In order to determine the caspase dependency in cisplatin or paclitaxel-induced 
apoptotic mechanism, MCF-7 wt and Bag-1 silenced cells were pre-treated with z-
LEHD-FMK (Caspase 9 inhibitor) or z-VAD-FMK (general caspase inhibitor) and 
the relative cell viability was measured by MTT Cell viability assay. MCF-7 wt and 
Bag-1 silenced cell were treated with these inhibitors for 24 h, then inhibitor-
included media was discarded and cisplatin or paclitaxel containing media was added 
to cells. It was obseved that both z-LEHD-FMK and z-VAD-FMK inhibits the cell 
viability loss caused by cisplatin or paclitaxel in MCF-7 wt and Bag-1 silenced cells.  
However, these inhibitors are less efficient in Bag-1 silenced cells than wt for the 
treatment of each drug. In addition, z-VAD-FMK which is a inhibitor of all caspases 
in the cell, was more effective to incrasethe cell viability in cisplatin or paclitaxel 
treated MCF-7 wt and Bag-1 silenced cells (Figure 3.17 a, b). 
 
 
 
Figure 3.17: Investigation the effect of cisplatin or paclitaxel on caspase dependency in 
MCF-7 wt and Bag-1 silenced cells. Cells were seeded at 1X10
3
 density in 96 well plates and 
pre-treated with z-LEHD- FMK and z-VAD-FMK for 24 h, then cells were exposed to 
cisplatin or paclitaxel. The relative cell viability loss was observed by MTT Cell viability 
assay (p value of graphic a) p= 0.0107and b) p<0.0001). 
3.2.4 Investigation the effect of Bag-1 silencing on cell cycle mechanism in 
cisplatin or paclitaxel-induced apoptosis 
In the cell cycle machineryCDKs and cyclins are important partners to regulate cell 
survival and cell proliferation. Cisplatin or paclitaxel induces apoptosis via causing 
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cell cycle arrest on G2/M phase. Cyclin B1 is controlled by CDK 1 at G2/M phase 
and cyclin D1 and CDK 4 regulate G1 phase together in the cell cycle. 
It was observed in Figure 3.18that cisplatin or paclitaxel treatment 
downregulatedCDK 1 expression at 24 h by 0.3 and 0.5-fold and later treatments 
abolished CDK 1 expression in MCF-7 cells. Transfection of Bag-1 siRNA showed a 
downregulationon CDK 1 expressionby 0.4-fold, alone. Combined treatment of 
cisplatin or paclitaxel caused a further downregulation on CDK 1 expression by 0.5-
fold. 
As a partner of CDK 1, similar results were obtained for the alternation of cyclin B1 
expression level in MCF-7 wt and Bag-1 silenced cells. Cisplatin downregulated 
cyclin B1 expression at a range 0.3to 0.6-fold in a time dependent manner. Paclitaxel 
caused significant downregulation at 24 h treatment by 0.4-fold and later treatment of 
this drug abolished cyclin B1 expression level.  
CDK 4 expression showed a stable expression profile in cisplatin treatment through 
72 h treatment as a downregulation on CDK 4 by 0.3-fold. 24 h treatment of 
paclitaxel did not significantly change the expression of CDK 4, but later treatment 
of this drug caused significant downregulation by 0.6 fold within 72 h. Bag-1 
silencing downregulatedCDK 4 expression by 0.4-fold, alone. Combined treatment 
of cisplatin caused 0.5-fold or paclitaxel caused 0.8-fold downregulation on CDK 4 
expression profile. 
In addition, transfection of cells with Bag-1 siRNA caused 0.4-fold downregulation 
on cyclin D1 expression level and combined treatment of cisplatin with Bag-1 
siRNA further enhanced the downregulatory effect by 0.6-fold. Treatment of cells 
with paclitaxel in the presence of Bag-1 siRNA abolished cyclin D1 expression 
profile. 
The cell cycle inhibitor protein p21 was upregulated by 1.85-fold in Bag-1 silenced 
cells and combined treatment of cisplatin or paclitaxel with Bag-1 siRNA further 
upregulated p21 expression level by 1.3-fold (Figure 3.18 a,b ). 
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Figure 3.18: Determination the effect of Bag-1 silencing on cell cycle in cisplatin or 
paclitaxel induced apoptosis. Cells were seeded at 1X10
6
density in 60 mm plates and treated 
with cisplatin or paclitaxel for 24 h. Bag-1 siRNA was transfected to MCF-7 cells for 48 h 
and the IC50 value of cisplatin or paclitaxel was performed to Bag-1 silenced MCF-7 cells. A 
total 20 g of protein lysate was loaded in 12% SDS page gel.  
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3.3 Investigation the functional role of Bag-1 over-expression in cisplatin or 
paclitaxel-induced apoptosis 
3.3.1 Investigation Bag-1 protein expression level in various cancer cells 
In order to perform the transfection experiment in appropriate cell line, the 
expression level of Bag-1 protein was investigated in different types of cancer cells. 
Breast cancer (MCF-7, MDA-MB-231), colon cancer (HCT-116, Caco-2) and 
prostate cancer (DU145, PNT1A) cells were used for this experiment. It was 
observed in Figure 3.19 expression profiles of all Bag-1 isoforms varied among cell 
types. Bag-1S expression level showed higher expression profile than Bag-1M in 
MCF-7, HCT-116, DU145 and PNT1A. However, in MDA-MB-231 breast cancer 
cells, Bag-1S showed a lower expression profile than Bag-1M isoform. Although, 
Bag-1L was determined as the least expressed isoform of Bag-1 in all types of cancer 
cells, HCT116 colon cancer and PNT1A prostate epithelium cells showed higher 
expression profile of Bag-1L comparing with other types of cancer cells . It was 
observed that Caco-2 colon cancer cell line did not exert any expression level profile 
of Bag-1 isoforms in these conditions. According to the result, MCF-7 cells were 
determined as a good candidate to investigate the functional role of Bag-1L isoform 
in drug-induced apoptosis. 
 
 
Figure 3.19: Bag-1 expression profiles in various cancer cell lines.Total protein lysates were 
isolated from breast, colon, prostate and colon cancer cells and determined by 12% SDS-
PAGE gel electrophoresis. 
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3.3.2 Optimization of TAP-tagged Bag-1L overexpression in MCF-7 breast 
cancer cells 
In order to optimize the overexpression of TAP-tagged Bag-1L, cells were 
transfected with different concentrations of lipid formulated transfection reagent and 
DNA complex as it was mentioned in Material-Methods 2.1.4.3. In Figure 3.20 
transfection efficiency of TAP-tagged BAG-1L included plasmid vector was 
analyzed with the differences in cellular morphology (Figure 3.20 a) and the 
expression profile of Bag-1 which was determined by immunoblotting (Figure 3.20 
b). Cells were transfected with 4, 6, 8 μl of Transfection reagent and plasmid DNA 
complex (2 g/l) and cells were grown in 100-700 mg/ml Geneticin (G418) 
included DMEM media for selection of colonies. Transfected cells was shown as 
round shaped and observed colony formations in all different ratios of transfection to 
compare with untransfected control cells. TAP-tagged Bag-1L transfection was 
confirmed with immunoblotting and it was observed that transfected cells showed 
TAP-tagged Bag-1L expression profile compared with the parental cells.  
Different transfection ratios did not show any significant increase on TAP-tagged 
Bag-1L, therefore the lowest transfection ratio was used in further experiments as an 
appropriate transfection ratio. 
 
 
Figure 3.20: Optimization of Bag-1 gene transfer was performed via colony selection and 
immunoblotting assay in MCF-7 cells. (a)TAP-tagged Bag-1L included plasmid vector was 
transfected to MCF-7 cells with various concentrations of transfection reagent:DNA ratio 
and were grown in 100-700 μg/ml Geneticin included DMEM for selection of colonies. 
Arrows indicate live MCF-7 cells. (b)MCF-7 cells were transfected with TAP-tagged BAG-
1L isoform for 48 h and total protein lysates were determined by immunoblotting assay.  
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3.3.3 Stable transfection of TAP-tagged Bag-1L isoform increased the Bag-1 
expression profile 
In order to demonstrate the role of TAP-tagged Bag-1L on Bag-1 expression profile, 
cells were treated with cisplatin or paclitaxel in different time points (2-72 h) (Figure 
3.21 a, b). 
According to the overexpression of Bag-1 gene, control cells showed a higher Bag-1 
protein expression profile in all three isoforms to compare with MCF-7 wt cells 
which was shown in Figure 3.2. The expression profile of Bag-1S isoform did not 
show a significant alternation due to cisplatin treatment in Bag-1 overexpressed cells 
within 48 h treatment, but 72 h treatment of cisplatin caused 0.4-fold downregulation 
on Bag-1S expression level. Similar to cisplatin treatment, Bag-1S protein expression 
level didnor show significant change in a time dependent paclitaxel treatment. 
It was observed that Bag-1M isoform showed a stable expression profile within 48 h 
cisplatin treatment, but later treatment of cisplatin cause downregulation on Bag-1 
expression level by 0.7-fold. Although the expression level of Bag-1M isoform 
showed a decrease in the late time point for cisplatin treatment, it showed more Bag-
1M expression profile than MCF-7 wt cells which was mentioned in Figure 3.2. 
Similar to cisplatin results, paclitaxel also showed stable Bag-1M expression profile 
in a time dependent manner.  
Bag-1L isoform showed similar expression profile in a time dependent cisplatin 
treated MCF-7 cells to compare with untreated control cells within 48 h, but 72 h 
cisplatin treatment downregulated Bag-1 expression 0.65-fold. In contrast, Bag-1L 
expression did not show any downregulation against paclitaxel treatment in a time 
dependent treatment (Figure 3.21 a, b).  
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Figure 3.21: The expression level of Bag-1 isoforms was altered depended upon Bag-1 
overexpression in time dependent cisplatin (a) or paclitaxel (b) treatments in MCF-7 
cells.Following cisplatin or paclitaxel treatment of MCF-7 wt and Bag-1L overexpressed  
cells in time dependent manner, total protein lysates were analyzed by immunoblotting 
assay. -actin was used as a loading control.  
 
3.3.4 Bag-1L over-expression promoted the proliferation rate of cisplatin or 
paclitaxel treated MCF-7 cells 
In order to determine the effect of Bag-1L overexpression on the proliferation rate of 
cisplatin or paclitaxel treated MCF-7 cells, trypan blue dye exclusion assay was 
performed (Figure 3.22 a, b). According to the result, Bag-1L overexpressed  cells 
showed higher proliferation rate than MCF-7 wt cells in 24, 48 and 72 h time 
periods. Cisplatin suppressed the proliferation rate about 0.3-fold in both 24 h 
cisplatin treated wt and Bag-1L overexpressed cells. However, 48 h cisplatin 
treatment increase the suppression on the profileration rate about 0.2-fold in wt cells, 
Bag-1L overexpressed cells showed a cisplatin resistant phenotype as shown the 
stable viable cell number with 24 h treatment. Following 72 h treatment of cisplatin, 
wt cells showed 0.7-fold decrease on cell proliferation but Bag-1L overexpressed 
cells displayed about 0.5-fold decrease on cell proliferation (Figure 3.22 a). 
However, paclitaxel decreased the viable cell number about 0.4, 0.5 and 0.6-fold in 
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24, 48 and 72 h treatment in MCF-7 wt cells, Bag-1L overexpressed cells showed 
0.3, 0.4 and 0.4 in 24, 48 and 72 h paclitaxel treatment. Bag-1L overexpressed cells 
were showed protection against paclitaxel in these time periods (Figure 3.22 b). 
 
 
Figure 3.22: Bag-1L overexpression enhanced the viable cell number by inducing 
proliferation rate of cisplatin (a) or paclitaxel (b) treated MCF-7 cells. MCF-7 wt and Bag-
1L overexpressed  cells were seeded at 1x10
5 
density in 6-well plates and treated with 50 M 
cisplatin (a) or 50 nM paclitaxel (b) for 24, 48, 72 h. According to the time points, cells were 
counted each day for 3 days using Trypan blue dye exclusion assay. Lines represent 
unstained viable cell numbers.  
3.3.5 Bag-1L overexpression decreased the apoptotic potential of cisplatin or 
paclitaxel 
In order to investigate the role of Bag-1L overexpression in cisplatin or paclitaxel-
induced apoptosis, MCF-7 wt and Bag-1L overexpressed cells were treated with 
various concentrations of cisplatin or paclitaxel for 24 h (Figure 3.23 a, b). Treatment 
of 15, 30 and 50 M cisplatin caused 1, 1.2 and 1.3-fold apoptotic induction to 
compare with untreated cells. However, Bag-1L overexpression displayed about 1, 
1.1 and 1.1.-fold apoptosis in 15, 30 and 50 M cisplatin treatment. Bag-1L 
overexpression decrease the apoptotic induction in dose dependent cisplatin 
treatment (Figure 3.23 a). Exposure 15, 30 and 50 nM paclitaxel led 1.2, 1.4 and 1.6-
fold increase on apoptosis to compare with parental cells. However, Bag-1L 
overexpression decreased the apoptotic induction by 0.1, 0.2 and 0.3-fold to compare 
with MCF-7 wt cells (Figure 3.23 b). 
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Figure 3.23:Bag-1L overexpression decreased the apoptotic effect of cisplatin or paclitaxel 
in MCF-7 cells.Cells were seeded at 1x10
4
 density in 96-well plates and treated with 
cisplatin (15- 50 M) (a)or paclitaxel (15- 50 nM) (b) for 24 h. Apoptosis was determined by 
cell death Elisa apoptosis assay according to the manufactorer instructions. 
3.3.6 Overexpression of Bag-1L led to morphological changes in cisplatin or 
paclitaxel-induced apoptosis 
In order to demonstrate the effect of Bag-1L overexpression onmorphological 
changes resulted from cisplatin or paclitaxel-induced apoptosis, cells were stained 
with specific dyes in time dependent drug treatment.  
3.3.6.1 Propidium iodide 
As mentioned Figure 3.1.7.1.PIwas used to identify dead cells in the cell population. 
It was observed in Figure 3.24 that exposure of cells with cisplatin or paclitaxel in 
time dependent manner (24, 48 h) led to increase in dead cell numbers in MCF-7 wt 
cells. Treatment of Bag-1L overexpressed cells with cisplatin or paclitaxel for 24 h 
displayed similar dead cell number with MCF-7 wt cells. Following 24 h treatments 
of these drugs, BAG-1L overexpression starts a protection against cisplatin and 
paclitaxel. It was observed that there was a significant decrease on dead cell numbers 
in 48 h cisplatin or paclitaxel treated MCF-7 cells. 
3.3.6.2 DiOC6 staining 
It was pointed out in Figure 3.25. DiOC6 was used to determine the alternations on 
mitochondrial membrane disruptions resulted from chemotherapeutic agent-induced 
apoptosis. DiOC6 included from live cells and stained green, but the staining of this 
dye reduce in drug-treated apoptotic cells. It was observed in Figure 3.25although, 
both untreated MCF-7 wt and Bag-1L overexpressed cells displayed the highest 
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DiOC6 stained viable cell numbers, control Bag-1L overexpressed cells formed 
many colonies. Exposure of cells with cisplatin or paclitaxel for 24 and 48 h, 
decreased the viable cell numbers in MCF-7 wt cells. Both drugs were effective to 
disrupt mitochondrial membrane and induce apoptosis in Bag-1L overexpressed  
cells, this effect was shown with the viable cell number decrease in 24 h cisplatin or 
paclitaxel treated Bag-1L overexpressed cells. However, Bag-1L overexpressed cells 
displayed a protection against cisplatin or paclitaxel through 48 h treatment that was 
observed in increase of viable cell numbers at this time period.  
3.3.6.3 Acridine orange 
In order to determine apoptotic cells depended upon the binding of DNA, acridine 
orange staining was performed. In Figure 3.26 control MCF-7 wt and Bag-1L 
overexpressed cells displayed bright green nuclei and intact membrane formation. 
Treatment of cisplatin or paclitaxel for 24 h increased the signs of apoptosis as 
fragmented DNA, and apoptotic body formationin MCF-7 wt and Bag-1L 
overexpressed cells. In contrast, 48 h cisplatin or paclitaxel treated Bag-1L 
overexpressed cells showed less red and dots, which was presented DNA 
fragmentation, and lysosomic compounds that referred apoptotic pH decrease. 
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Figure 3.24: The effect of Bag-1L overexpression on cisplatin or paclitaxel-induced apoptosis was observed by PI staining.MCF-7 wt or Bag-1L 
overexpressed  were treated with cisplatin or paclitaxel in time dependent manner. Apoptotic dead cells were determined as red dots.Images were taken at 
200x expansion of cells. 
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Figure 3.25: Determination of mitochondrial membrane potential loss (MOMP) was performed following cisplatin or paclitaxel in MCF-7 wt and Bag-1L 
overexpressed  cells.MCF-7 wt and Bag-1L overexpressed  cells were treated with cisplatin or paclitaxel im time dependent manner. The loss of MOMP 
observed by DiOC6 staining as green dots. Images were taken at 200x expansion of cells. 
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Figure 3.26: Determination the effect of Bag-1L overexpression in cisplatin or paclitaxel-induced apoptosis was observed by Acridine Orange (AO) staining. 
MCF-7 wt and Bag-1L overexpressed  cells were treated with cisplatin or paclitaxel in time dependent manner. Nuclear condensation and lysosomic 
compounds were observed by AO staining.Images were taken at 200x expansion of cells. 
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3.4 Bag-1 expression level altered the polyamine metabolism in cisplatin or 
paclitaxel-induced apoptosis in MCF-7 cells 
Polyamines are crucial amine-derivative organic compounds that regulate cell 
proliferation and cell survival mechanisms. Put, Spd, Spmare main polyamines found 
in all eukaryotes and elevated level of intracellular polyamine contents are related 
with progression of various cancers. Anti-cancer chemotherapeutic drugs are used to 
decrease the polyamine levels in the cell by increase the ROS generation and leads to 
apoptosis. ODC regulates the biosynthetic pathway of polyamines with c-myc 
oncogene and increase the intracellular polyamine content. On the other hand, PAO, 
SSATand Spermine oxidase (SMO) are catabolic enzymes that responsible to 
decrease the polyamine level by inducing the efflux of these organic compounds 
from cell. 
3.4.1 Bag-1 expression level had an effect on polyamine metabolic enzymes in 
cisplatin or paclitaxel-induced apoptosis in MCF-7 cells 
We investigated the role of Bag-1 expression level on polyamine metabolism in 
cisplatin or paclitaxel-induced apoptosis. In Figure 3.27 the expression profiles of 
ODC, PAO and SSAT were investigated in Bag-1 siRNA transfection alone and 
combination with cisplatin or paclitaxel in MCF-7 cells(Figure 3.27 a). 
The least expression profile of PAO and SSAT was shown in untreated control cells. 
Transiently transfection of Bag-1 siRNA downregulated ODC expression by 0.35-
fold in MCF-7 cells.Combined treatment cisplatin or paclitaxel with Bag-1 siRNA 
further downregulated ODC expression by 0.45 fold to compare with nontransfected 
control cells. 
Bag-1 silencing upregulated PAO expression by 0.5-fold alone and treatment of cells 
with cisplatin or paclitaxel enhanced theepregulatory effect by 0.7-fold to compare 
with parental control cells. 
Similar to PAO upregulartion, SSAT also upregulated by Bag-1 silencing by 0.3-
fold, and combination of cisplatin or paclitaxel further upregulated SSAT expression 
by 0.4 and 0.5-fold to compare with control cells.  
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Figure 3.27: The expression level of Bag-1 altered the expression levels of polyamine 
metabolic pathway enzymes in Bag-1 silenced MCF-7 cells.Cells were seeded at 
1X10
6
density in 60 mm plates and treated with cisplatin or paclitaxel for 24 h. Bag-1 siRNA 
was transfected to cells for 48 h, then cisplatin or paclitaxel was performed to Bag-1 silenced 
MCF-7 cells. A total 20 g of protein lysate was loaded in 12% SDS page and probed with 
PAO, ODC and SSAT. -actin was performed as a loading control.  
 
3.4.2 Bag-1 expression levels altered the intracellular polyamine content in 
cisplatin or paclitaxel treated MCF-7 cells 
We analyzed the effect of Bag-1 expression level on polyamine content of cisplatin 
or paclitaxel treated MCF-7 wt, Bag-1L overexpressed and Bag-1 silenced cells via 
High Pressure Liquid Chromatography (HPLC) (Figure 3.28). Cisplatin showed a 
decrease on Put levels in MCF-7 wt cells in time dependent manner and significantly 
decreased the Spd levels in 24 h treatment and longer treatments of cisplatin did not 
exert a significant change on Spd levels. Spm amount was the least of three organic 
compounds in untreated control cells and this amount was not changed depended 
upon drug treatment in MCF-7 wt cells. (Figure 3.28 b) 
Paclitaxel decreased the Put level for 24 h and 48 h treatments but 72 h treatment of 
paclitaxel led an increase on Put level. Spd levels were significantly decreased at 24 
h treatment but increased at 48 h and 72 h treatments. Spm levels decreased in time 
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dependent manner in MCF-7 wt cells. (Figure 3.28 c)However, Put levels decreased 
in time dependent cisplatin treatment in Bag-1L overexpressed cells, the level of Put 
was higher at 72 h cisplatin treatment to compare with MCF-7 wt cells. Spd levels 
decreased at 24 h treatment of cisplatin and showed a stable amount at 48 h treatment 
but the amount of Spd was significantly increased at 72 h treatment of cisplatin in 
MCF-7 Bag-1L overexpressed cells. Also, Spd levels were higher in MCF-7 Bag-1 
cells than wt cells.  Spm levels slightly decreased at 24 h but increased in 48 h and 72 
h cisplatin treatments. (Figure 3.28 d)Put level was decreased at 24 h treatment of 
paclitaxel that showed a stable amount at 48 h and 72 h treatment. Spd levels 
displayed slight decrease in time dependent paclitaxel treatment in MCF-7 Bag-1L 
overexpressed cells. The amount of Spm increased at 24 h paclitaxel treatment but 
decreased at later treatments of paclitaxel. (Figure 3.28 e) Transiently transfection of 
Bag-1 siRNA decreased the intracellular level of Put and Spd but increased Spm. 
Combination with cisplatin and Bag-1 siRNA further decreased the level of Put, Spd 
and Spm levels. However, treatment of Bag-1 silenced cells with paclitaxel was 
increased the Put levels, Spd and Spm levels were increased to compare with 
untransfected cells.  
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Figure 3.28: Bag-1 expression altered the intracellular protein content in MCF-7 cells.MCF-
7 wt, Bag-1L overexpressed  or Bag-1 silenced cells were seeded at 1X10
6
 density in 60 mm 
plates and treated with cisplatin or paclitaxel for 24, 48 and 72 h. PA content was determined 
by benzoylation method via HPLC. Colums represent the means ± SD of four independent 
trials with at least four replicates.  
 
3.4.3 The effect of Bag-1 expression on ROS generation in cisplatin or 
paclitaxel-induced apoptosis 
As mentioned above, chemotherapeutic agents were used to deplete the intracellular 
polyamine content and led the cells to apoptotic process by inducing the ROS 
generation as by-products of drug-induced polyamine catabolism. To investigate 
generation and accumulation of ROS due to cisplatin or paclitaxel treatment alone or 
combination with Bag-1 siRNA, ROS indicator CM-H2DCFDA was used in MCF-7 
cells. In Figure 3.29the relative ROS generation was investigated depended on 
cisplatin or paclitaxel treatment in MCF-7 wt, Bag-1L overexpressed  and Bag-1 
silenced cells. (Figure 3.29 a)Cisplatin or paclitaxel increased the ROS level in time 
dependent manner (24, 48 h) in MCF-7 wt cells. Both drugs were effective to 
increase the level of ROS generation in Bag-1L overexpressed cells to comparing 
with untreated Bag-1L overexpressed cells. However, the ROS generation level in 48 
h cisplatin or paclitaxel treated Bag-1L overexpressed cells were less than 48 h 
cisplatin or paclitaxel treated wt cells. (Figure 3.29 b)Silencing of Bag-1 increased 
the ROS generation comparing with non-silenced control cells, but further increase 
on ROS generation were shown in combine treatment of cisplatin or paclitaxel with 
Bag-1 siRNA. 
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Figure 3.29: The generation of ROS was enhanced in the presence of Bag-1 siRNA.Cells 
were seeded at 1X10
5 
densities into 6 well plates and treated with cisplatin or paclitaxel for 
24 and 48 h. Bag-1 silenced cells were treated with cisplatin or paclitaxel for 24 h. Then, 
DCFH-DA was performed for 30 min and ROS accumulation was estimated by fluometer 
(Excitation: 485 nm, emission: 520 nm). 
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4.  DISCUSSION  
Bag-1 (Bcl-2 athanogene) protein was discovered in 1990s via its binding capability 
to anti-apoptotic Bcl-2 protein. Bag-1 protein is expressed in various cancer types 
such as breast, colon and prostate and elevated expression level of this protein was 
related with the development or progression of cancer cells [128]. Bag-1 has several 
interaction partners such as Bcl-2, nuclear hormone receptors, growth factor 
receptors, Raf-1 kinases and Heat Shock Proteins (Hsp70/Hsc70) and DNA, 
therefore Bag-1 plays significant roles to promote cell growth, cell survival, cell 
migration and suppression of apoptosis in different types of cancer cells such as 
breast or gastric cancer cells [129, 130]. Considering these important interaction 
partners that trigger survival mechanisms of cancer cells, as a promising molecule, 
Bag-1 gains significance in the treatment of various cancer cells.  
In the field of cancer treatment, surgery, radiotherapy, hormonal therapy and 
chemotherapy have been used for a long time to decrease the cell viability of cancer 
cells. Cisplatin and paclitaxel are the most commonly used chemotherapeutics in the 
treatment of cancer cells. Cisplatin is a platinum-derived chemotherapeutic agent that 
forms DNA adducts and inhibits replication of DNA, paclitaxel is a member of 
Taxanes that are microtubule-stabilizing agents, and both drugs were effective to 
induce apoptosis in different ways [131].Even though it is widely accepted as the 
drug treatments are better ways in the treatment of cancer, because of the cytotoxic 
side effects of drugs or development of resistance mechanism against drugs, the need 
for the alternative approaches, such as small interfering RNAs (siRNA), are raised 
asanti-cancer therapeutics. Transfection of gene specific siRNA into cells caused 
downregulation of gene expression at translation process without any toxicity [132]. 
In this study, we determined the silencing effect of Bag-1 in cisplatin or paclitaxel-
induced apoptotic mechanism in MCF-7 breast cancer cells. According to the MTT 
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cell viability assay 50M cisplatin or 50 nM paclitaxel was determined as IC50 value 
of each drug in cells. These concentrations were used at further experiments to 
investigate the role of Bag-1 silencing in drug-induced apoptosis mechanism (Figure 
3.1).  
It was observed from previous studies cisplatin was effective to decrease cell 
viability in different cancer cells such as HeLa [133]. Cisplatin or paclitaxel was able 
to down-regulate Bag-1 protein isoforms in a time dependent manner (Figure 3.2).  
Inspite of the fact that there are previous studies about the effect of cisplatin or 
paclitaxel on Bcl-2 expression level but not many of them engage this research by 
using cisplatin or paclitaxel to determine the expression level of Bag-1, Bcl-2 
associated protein. Previous studies showed that both cisplatin or paclitaxel exerted 
down-regulatory effects on Bcl-2 expression levels but on the other hand, cisplatin or 
paclitaxel resistant cells displayed higher Bcl-2 expressions [134]. 3l Bag-1 
siRNA:transfer reagent complex was selected as a non-cytotoxic concentration of 
Bag-1 siRNA and transient transfection of Bag-1 siRNA was effective to suppress 
Bag-1 expression in each isoform (Figure 3.3).Although, it was observed that 
cisplatin or paclitaxel reduced the proliferation ratio of MCF-7 cells in a time 
dependent manner,Bag-1 silencing further decreased the cell proliferation rate in the 
presence or absence of drugs (Figure 3.6). In addition, both drugs caused apoptosis in 
a dose dependent manner, and the selected dose for drugs; 50 M cisplatin or 50 nM 
paclitaxel, showed the highest apoptotic ratio (Figure 3.7). Co-treatment of Bag-1 
siRNA and drugs enhanced the apoptotic potential of the drugs. A similar type of 
effect of Bag-1 was also observed earlier for human lung adenocarcinoma cell 
lines[135]. Therefore, we suggest that Bag-1 siRNA treatmentcan be a new potential 
approach for potentiating the drug-induced apoptosis. To understand whether drug-
induced cell viability loss caused by apoptosis or not, important signs of apoptosic 
markers were investigated by various staining methods, which confirmed the 
presence of apoptotic cell death. 
Several studies analyzed the effect of drugs or apoptotic inducerson cell cycle 
machinery and sub-G1 represent the accumulation of apoptotic cells [136, 137]. PI 
staining with flow cytometry analyzed changes in the cell cycle phases caused by the 
apoptotic effect of cisplatin or paclitaxel. Bag-1 silencing was not effective to 
accumulate cells in sub-G1 but although, treatments of both drugs enhanced the 
85 
accumulation of cells at sub-G1, paclitaxel was more effective to induce apoptosis 
than cisplatin (Figure 3.13). These data confirmed that transfection of cells with Bag-
1 siRNA alone did not induce apoptosis but combination with cisplatin or paclitaxel 
induce apoptosis and sub-G1 accumulation.  
Chemotherapeutic agents are functional for inducing of cell death mechanism 
especially apoptosis,but on the contrary treatment of chemotherapeutic drugs for long 
periods caused resistance against these drugs [138, 139]. Therefore, targeting 
resistance mechanism gains importance for anticancer therapy. For this purpose, 
downregulation of some genes are potential targeting way to eliminate resistance 
mechanism of anti-cancer drugs [140]. In our experiments we figured out the 
apoptotic characteristics of both drugs and/or silencing of Bag-1 related with Bcl-2 
family members. As shown in previous studies, Bcl-2 family consists of pro-
apoptotic and anti-apoptotic members to change the apoptotic decision against drugs. 
The decision of apoptotsis is related with the upregulation of pro-apoptotic Bcl-2 
family proteins (Bax, Bak, Bid, Bad, Bim). On the other hand, upregulation of anti-
apoptotic Bcl-2 proteins (Bcl-2, Bcl-XL, Mcl-1) suppress apoptosis and lead cell to 
survival (Figure 3.14). 
In addition,some chemotherapeutics induce apoptosis by p53 dependent manner, this 
tumor suppressor protein is upregulated with drug treatment andcause increases on 
Noxa and PUMA expression levels that are target molecules of p53 in drug-induced 
apoptosis[141]. We investigate the expression levels of Bcl-2 family proteins in drug 
treated MCF7 wt and Bag-1 silenced cells (Figure 3.15). Although time dependent 
apoptotic induction of each drug was different, they were able to down-regulate anti-
apoptotic Bcl-2 and Bcl-XLexpression levels. Time depenent treatment of cisplatin 
cause significant cleavage on Bcl-2 protein. It was shown in previous studies that 
exposure of cells with cisplatin induced the cleavage of Bcl-2 protein to activate the 
apoptosis mechanism [142]. In addition, combined treatment of Bag-1 with cisplatin 
or paclitaxel further downregulated this anti-apoptotic protein expression levels. In 
contrary, drugs effectively induced apoptotis in the presence or absence Bag-1 
siRNA by upregulating the expression levels of pro-apoptotic Bcl-2 family proteins 
(Bax, Bak, Bid, Bad). Time dependent cisplatin treatment upregulatedp53, Noxa and 
PUMA but paclitaxel showed stable Noxa and PUMA expression profile. We 
suggested that cisplatin induced p53-mediated apoptosis in time dependent manner in 
MCF-7 cells but paclitaxel did not. 
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In order to investigate the role of cisplatin or paclitaxel and/or Bag-1 siRNA on 
caspase-dependent apoptosis, we determined the expression levels of caspase 9, 
caspase 7 and caspase 2 in drug treated MCF-7 wt and Bag-1 silenced cells (Figure 
3.16). Cysteine protease caspases have important roles in apoptotic pathway to 
transmit the apoptotic signal into other caspases. caspase 9 is an initiator caspases 
and responsible for either extrinsic or mitochondrial apoptotic pathways. Active 
caspase 9 activates effector caspases such as caspase 3 or caspase 7 [143]. Other 
initator caspase is caspase 2 is activated via DNA-damage stimuli and induce 
apoptosis via Bax-mediated mitochondrial apoptotic pathway.However, full caspase 
9 and 7 was observed in control cells, cleavage of these proteins significantly 
enhanced following cisplatin or paclitaxel treatment. In addition, expression level of 
caspase 2 was upregulated in time dependent cisplatin or paclitaxel treatment. 
Silencing of Bag-1 enhanced the caspase 9 and caspase 7 cleavage and further 
upregulated caspase 2, PARPis a substrate for caspases and responsible for DNA 
repair and transcriptional regulation and cleavages of PARP associated with the 
fragmented DNA caused by apoptosis. However, untreated parental cells did not 
exert cleaved PARP expression, cisplatin or paclitaxel upregulatedcleaved PARP 
expression in time dependent manner. Silencing of Bag-1 did not cause PARP 
cleavagealone, combination of Bag-1 siRNA with cisplatin or paclitaxel significantly 
enhanced the cleavage of PARP.  
Studying the pro- and anti-apoptotic protein levels, it is understood that both Bag-1 
siRNA and drug treatments follow caspase dependent apoptotic pathway (Figures 
3.16, 3.17). Once the caspases are inhibited using specific molecules, we observed 
enhanment in the cell viability revealing caspase dependent effect of the treatments 
(Figure 3.17).  
Cell division or cell survival cycle is controlled by cyclin and cyclin dependent 
kinases (CDKs). At the phases of cell cycle cyclin D1/CDK4-6 complex is 
responsible from G1, cyclin E/CDK 2 complex regulates G1/S phase, cyclin A/CDK 
2 complex controls S/G2 and cyclin B1/CDK 1 complex controls G2/M phase[144]. 
Cisplatin or paclitaxel induces apoptosis via mitochondria-mediated apoptotic 
pathway and they cause G2/M arrest in the cancer cells[145, 146]. This drugs 
downregulatedcyclin B1 and CDK 1 expressions in time dependent manner. 
Silencing of Bag-1 also downregulatedCDK 1 expression with cisplatin or paclitaxel 
treatment,but, cyclin B1 did not exert significant downregulation agaist combined 
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treatment of Bag-1 siRNA with cisplatin or paclitaxel. The indicator of G1 phase, 
CDK 4 was downregulated in time dependent drug treatment and Bag-1 siRNA 
transfection. Treatment of paclitaxel was more efficient to down-regulate CDK 4 
than treatment of cisplatin. We concluded that both drugs were able to inhibit cell 
division process via down-regulating cyclin/CDK complexes that have roles in G1 
and G2/M (Figure 3.18). 
To understand the effect of Bag-1 expression levels in drug induced apoptotic 
mechanism, we transfected Bag-1L included plasmid vector to MCF-7 cells and 
stable Bag-1L overexpressed colonies were selected (Figure 3.20). The 
overexpression of Bag-1L caused upregulation on all Bag-1 isoforms and MCF-7 
Bag-1 overexpressed cells showed a protection against cisplatin or paclitaxel late 
treatment periods (Figure 3.21).It was mentioned that Bag-1 has three isoforms 
producing via alternative translation initiation sites from the same mRNA. Therefore, 
overexpression of Bag-1L leads overexpression of isoforms in the cell.  
Bag-1 overexpression gains importance to be a promising target for diagnosis or 
treatment cancer cells. Previous studies showed that overexpression of Bag-1 alone 
or co-overexpression with some interaction partners prevent drug-induced cell death, 
promotes tumor cell survival and progression , resistance to chemotherapeutic drugs 
in various cancer cells such as ovarian, colorectal, breast and cervical cancer cells. 
Therefore, we examined the effect of Bag-1 overexpression on cisplatin or 
paclitaxel-induced apoptosis in MCF-7 cells. We found that overexpression of Bag-1 
enhanced the proliferation rate of untreated control cells. However, following drug 
treatment the proliferation rate of MCF-7 cells were decrease in time dependent 
manner, Bag-1 overexpressed cells showed a stable proliferation rate following 48 h 
drug treatments (Figure 3.22). In addition MCF-7 Bag-1 overexpressed cell 
displayed less apoptotic fold change than MCF-7 wt cells in dose dependent cisplatin 
or paclitaxel treatment (Figure 3.23). It confirms that Bag-1 overexpression 
suppresses in drug-induced apoptosis.  
In order to examine the morphological changes in cisplatin or paclitaxel-induced 
apoptosis in MCF-7 wt and Bag-1 overexpressed cells, PI, DiOC6, AO staining 
performed (Figure 3.24,3.25, 3.26,). It was observed that Bag-1 overexpressed cells 
showed less PI stained dead cell numbers following 48 h cisplatin or paclitaxel 
treatment. However, DiOC6 stained cells did not showed significant alternation in 
time dependent cisplatin treated MCF-7 wt or Bag-1 overexpressed cells, 48 h 
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paclitaxel treatment enhanced DiOC6 stained viable cell number compared to wt 
cells. AO staining was not effective to observe the anti-apoptotic effect of Bag-1 
overexpression in drug-treated MCF-7 cell, each cell types showed apoptotic body 
formation and ssDNA fragmentation. 
We concluded from overexpression studies, Bag-1 overexpression started within 48 
h, and overexpression of Bag-1 played a role to increase cell proliferation ratio or 
slight inhibition of apoptosis in cisplatin or paclitaxel-induced apoptosis. On the 
contrary, when we investigate changing the expression levels of apoptotic parameters 
such as pro-apoptotic or anti-apoptotic Bcl-2 family member protein or PARP 
cleavage, we could not observe the anti-apoptotic effect of Bag-1 in cisplatin or 
paclitaxel induced apoptosis. For instance, pro-apoptotic member of Bcl-2 family 
protein was further upregulated in Bag-1 overexpressed cells. In contrast, anti-
apoptotic Bcl-2 family member was further downregulated in Bag-1 overexpressed 
cells. In addition to this, we could not observe TAP-tag in any of immublotting 
analysis. We suggested that, TAP-tag which is 20 kDa, is large for this type of 
plasmid and it could be cleaved at any time of cell division process, therefore we 
could not observe the drug resistant phenotype. For these reasons, we decided to 
examine the effect of silencing of Bag-1 in cisplatin or paclitaxel-induced apoptosis. 
We clearly observe that, the effect of Bag-1 siRNA with drugs for inducing the 
apoptotic mechanism was more effective and certain than the effect of Bag-1 
overexpression for investigation the anti-apoptotic function of this protein.  
Lastly, we investigated the effect of Bag-1 in drug-induced apoptotic mechanism in 
association with polyamines. Polyamines are crucial amine derivatives for the 
regulation of cell survival, cell proliferation, biosytnthesis reactions such as protein 
synthesis, cancer development and apoptosis. Elevated levels of polyamines are 
related with the progression of various cancer cells. Therefore, depletion in the 
intracellular polyamine content is potential anti-cancer therapy with using inhibitors 
or chemotherapeutic drug to induce apoptosis.  
Decreasing intracellular polyamine content induces cytochrome c release fom 
mitochondria and induce mitochondria-mediated apoptosis[150]. In this study, we 
investigated the effect of Bag-1 expression level on biosynthetic ODC and catabolic 
PAO enzyme profile in cisplatin or paclitaxel treated MCF-7 cells (Figure 3.27.). 
ODC expression was higher in untreated parental cells compared to cisplatin or 
paclitaxel treated Bag-1 silenced cells. PAO expression was upregulated both in drug 
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treated Bag-1 silenced MCF-7 cells. Silencing of Bag-1 significantly downregulated 
ODC and upregulated PAO expression alone and combination with drug treatment in 
MCF-7 cell. We analyzed the intracellular polyamine content in cisplatin or 
paclitaxel treated MCF-7 wt, Bag-1 overexpressed and Bag-1 silenced cells (Figure 
3.28 ). Each drugs were effective to decrease Put levels, increase Spd levels but 
stable expression profile on Spm levels in MCF-7 wt cells in a time dependent 
manner. MCF-7 Bag-1 overexpressed cells showed similar expression profile with wt 
cells, instead of further increase was observed in Spd levels in time dependent drug 
treatment. Transfection of Bag-1 siRNA decreased the Put and Spd levels but 
increased Spm levels compared to wt cells. However, combined treatment of 
cisplatin decreased the Spd and Spm levels, paclitaxel increased Spd and Spm levels. 
In addition, the ROS generation was observed with ROS indicator CM-H2DCFDA 
and Bag-1 overexpression decreased the ROS generation but Bag-1 silencing 
significantly enhanced ROS generation in cisplatin or paclitaxel-induced apoptosis 
(Figure 3.29).  
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